[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5925 Engrossed in House (EH)]
<DOC>
115th CONGRESS
2d Session
H. R. 5925
_______________________________________________________________________
AN ACT
To codify provisions relating to the Office of National Drug Control,
and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Coordinated Response through
Interagency Strategy and Information Sharing Act'' or the ``CRISIS
Act''.
SEC. 2. OFFICE OF NATIONAL DRUG CONTROL.
(a) Redesignation.--The Office of National Drug Control Policy
shall be known as the ``Office of National Drug Control''.
(b) References.--Any reference in any other Federal law, Executive
order, rule, regulation, or delegation of authority, or any document of
or relating to the Office of National Drug Control Policy is deemed to
refer to the Office of National Drug Control.
(c) Codification.--Subtitle I of title 31, United States Code, is
amended by adding at the end the following new chapter:
``CHAPTER 10--OFFICE OF NATIONAL DRUG CONTROL
``subchapter i--office
``1001. Definitions.
``1002. Office of National Drug Control.
``1003. Administration of the Office.
``1004. National drug control program budget.
``1005. National drug control strategy.
``1006. Development of an annual national drug control assessment.
``1007. Monitoring and evaluation of national drug control program.
``1008. Coordination and oversight of the national drug control
program.
``1009. Emerging threats task force, plan, campaign.
``1010. National and international coordination.
``1011. Interdiction.
``1012. Treatment coordinator.
``1013. Critical information coordination.
``1014. Authorization of appropriations.
``subchapter ii--drug-free communities support program
``1021. Establishment of drug-free communities support program.
``1022. Program authorization.
``1023. Information collection and dissemination with respect to grant
recipients.
``1024. Technical assistance and training.
``1025. Supplemental grants for coalition mentoring activities.
``1026. Authorization for National Community Antidrug Coalition
Institute.
``1027. Definitions.
``1028. Drug-free communities reauthorization.
``SUBCHAPTER I--OFFICE
``Sec. 1001. Definitions
``In this chapter:
``(1) Agency.--The term `agency' has the meaning given the
term `executive agency' in section 102.
``(2) Appropriate congressional committees.--
``(A) In general.--The term `appropriate
congressional committees' means--
``(i) the Committee on the Judiciary, the
Committee on Appropriations, the Committee on
Health, Education, Labor, and Pensions, and the
Caucus on International Narcotics Control of
the Senate; and
``(ii) the Committee on Oversight and
Government Reform, the Committee on the
Judiciary, the Committee on Energy and
Commerce, and the Committee on Appropriations
of the House of Representatives.
``(B) Submission to congress.--Any submission to
Congress shall mean submission to the appropriate
congressional committees.
``(3) Demand reduction.--The term `demand reduction' means
any activity conducted by a National Drug Control Program
Agency, other than an enforcement activity, that is intended to
reduce or prevent the use of drugs or support or provide
treatment and recovery efforts, including--
``(A) education about the dangers of illicit drug
use;
``(B) services, programs, or strategies to prevent
substance use disorder, including evidence-based
education campaigns, community-based prevention
programs, collection and disposal of unused
prescription drugs, and services to at-risk populations
to prevent or delay initial use of an illicit drug;
``(C) substance use disorder treatment;
``(D) illicit drug use research;
``(E) drug-free workplace programs;
``(F) drug testing, including the testing of
employees;
``(G) interventions for illicit drug use and
dependence;
``(H) expanding availability of access to health
care services for the treatment of substance use
disorders;
``(I) international drug control coordination and
cooperation with respect to activities described in
this paragraph;
``(J) pre- and post-arrest criminal justice
interventions such as diversion programs, drug courts,
and the provision of evidence-based treatment to
individuals with substance use disorders who are
arrested or under some form of criminal justice
supervision, including medication assisted treatment;
``(K) other coordinated and joint initiatives among
Federal, State, local, and Tribal agencies to promote
comprehensive drug control strategies designed to
reduce the demand for, and the availability of, illegal
drugs;
``(L) international illicit drug use education,
prevention, treatment, recovery, research,
rehabilitation activities, and interventions for
illicit drug use and dependence; and
``(M) research related to any of the activities
described in this paragraph.
``(4) Director.--The term `Director' means the Director of
the Office of National Drug Control.
``(5) Drug.--The term `drug' has the meaning given the term
`controlled substance' in section 102(6) of the Controlled
Substances Act (21 U.S.C. 802(6)).
``(6) Drug control.--The term `drug control' means any
activity conducted by a National Drug Control Program Agency
involving supply reduction or demand reduction.
``(7) Emerging drug threat.--The term `emerging drug
threat' means the occurrence of a new and growing trend in the
use of an illicit drug or class of drugs, including rapid
expansion in the supply of or demand for such drug.
``(8) Illicit drug use; illicit drugs; illegal drugs.--The
terms `illicit drug use', `illicit drugs', and `illegal drugs'
include the illegal or illicit use of prescription drugs.
``(9) Law enforcement.--The term `law enforcement' or `drug
law enforcement' means all efforts by a Federal, State, local,
or Tribal government agency to enforce the drug laws of the
United States or any State, including investigation, arrest,
prosecution, and incarceration or other punishments or
penalties.
``(10) National drug control program.--The term `National
Drug Control Program' means programs, policies, and activities
undertaken by National Drug Control Program Agencies pursuant
to the responsibilities of such agencies under the National
Drug Control Strategy, including any activities involving
supply reduction, demand reduction, or State, local, and Tribal
affairs.
``(11) National drug control program agency.--The term
`National Drug Control Program Agency' means any agency (or
bureau, office, independent agency, board, division,
commission, subdivision, unit, or other component thereof) that
is responsible for implementing any aspect of the National Drug
Control Strategy, including any agency that receives Federal
funds to implement any aspect of the National Drug Control
Strategy, but does not include any agency that receives funds
for drug control activity solely under the National
Intelligence Program or the Military Intelligence Program.
``(12) National drug control strategy; strategy.--The term
`National Drug Control Strategy' or `Strategy' means the
strategy developed and submitted to Congress under section
1005.
``(13) Nonprofit organization.--The term `nonprofit
organization' means an organization that is described in
section 501(c)(3) of the Internal Revenue Code of 1986 and
exempt from tax under section 501(a) of such Code.
``(14) Office.--The term `Office' means the Office of
National Drug Control.
``(15) State, local, and tribal affairs.--The term `State,
local, and Tribal affairs' means domestic activities conducted
by a National Drug Control Program Agency that are intended to
reduce the availability and use of illegal drugs, including--
``(A) coordination and enhancement of Federal,
State, local, and Tribal law enforcement drug control
efforts;
``(B) coordination and enhancement of efforts among
National Drug Control Program Agencies and State,
local, and Tribal demand reduction and supply reduction
agencies;
``(C) coordination and enhancement of Federal,
State, local, and Tribal law enforcement initiatives to
gather, analyze, and disseminate information and law
enforcement intelligence relating to drug control among
domestic law enforcement agencies; and
``(D) other coordinated and joint initiatives among
Federal, State, local, and Tribal agencies to promote
comprehensive drug control strategies designed to
reduce the demand for, and the availability of, illegal
drugs.
``(16) Substance use disorder treatment.--The term
`substance use disorder treatment' means an evidence-based,
professionally directed, deliberate, and planned regimen
including evaluation, observation, medical monitoring, and
rehabilitative services and interventions such as
pharmacotherapy, behavioral therapy, and individual and group
counseling, on an inpatient or outpatient basis, to help
patients with substance use disorder reach recovery.
``(17) Supply reduction.--The term `supply reduction' means
any activity or program conducted by a National Drug Control
Program Agency that is intended to reduce the availability or
use of illegal drugs in the United States or abroad,
including--
``(A) law enforcement outside the United States;
``(B) domestic law enforcement;
``(C) source country programs, including economic
development programs primarily intended to reduce the
production or trafficking of illicit drugs;
``(D) activities to control international
trafficking in, and availability of, illegal drugs,
including--
``(i) accurate assessment and monitoring of
international drug production and interdiction
programs and policies; and
``(ii) coordination and promotion of
compliance with international treaties relating
to the production, transportation, or
interdiction of illegal drugs;
``(E) activities to conduct and promote
international law enforcement programs and policies to
reduce the supply of drugs;
``(F) activities to facilitate and enhance the
sharing of domestic and foreign intelligence
information among National Drug Control Program
Agencies, relating to the production and trafficking of
drugs in the United States and in foreign countries;
``(G) activities to prevent the diversion of drugs
for their illicit use; and
``(H) research related to any of the activities
described in this paragraph.
``Sec. 1002. Office of National Drug Control
``(a) Establishment of Office.--There is established in the
Executive Office of the President an Office of National Drug Control,
which shall--
``(1) lead the national drug control effort, including
coordinating with Nation Drug Control Program Agencies;
``(2) coordinate and oversee the implementation of the
national drug control policy, including the National Drug
Control Strategy;
``(3) assess and certify the adequacy of National Drug
Control Programs and the budget for those programs;
``(4) monitor and evaluate the effectiveness of national
drug control policy efforts, including the National Drug
Control Program Agencies' programs, by developing and applying
specific goals and performance measurements and tracking
program-level spending;
``(5) identify and respond to emerging drug threats related
to illicit drug use;
``(6) administer and evaluate grant programs in furtherance
of the National Drug Control Strategy; and
``(7) facilitate broad-scale information sharing and data
standardization among Federal, State, and local entities to
support the national drug control efforts.
``(b) Director of National Drug Control and Deputy Director.--
``(1) Director.--
``(A) In general.--There shall be at the head of
the Office a Director who shall hold the same rank and
status as the head of an executive department listed in
section 101 of title 5.
``(B) Appointment.--The Director shall be appointed
by the President, by and with the advice and consent of
the Senate, and shall serve at the pleasure of the
President.
``(2) Deputy director.--
``(A) In general.--There shall be a Deputy Director
who shall report directly to the Director, be appointed
by the President, and serve at the pleasure of the
President.
``(B) Responsibilities.--The Deputy Director
shall--
``(i) carry out the responsibilities
delegated by the Director; and
``(ii) be responsible for effectively
coordinating with the each Coordinator
established under this chapter.
``(c) Responsibilities.--
``(1) Policies, goals, objectives, and priorities.--The
Director shall assist the President in directing national drug
control efforts, including establishing policies, goals,
objectives, and priorities for the National Drug Control
Program that are based on evidence-based research.
``(2) Consultation.--To formulate the National Drug Control
policies, goals, objectives, and priorities, the Director--
``(A) shall consult with--
``(i) State and local governments;
``(ii) National Drug Control Program
Agencies;
``(iii) each committee, working group,
council, or other entity established under this
chapter, as appropriate;
``(iv) the public;
``(v) appropriate congressional committees;
and
``(vi) any other person in the discretion
of the Director; and
``(B) may--
``(i) establish advisory councils;
``(ii) acquire data from agencies; and
``(iii) request data from any other entity.
``Sec. 1003. Administration of the Office
``(a) Employment.--
``(1) Authority of the director.--The Director may select,
appoint, employ, and fix compensation of such officers and
employees of the Office as may be necessary to carry out the
functions of the Office under this chapter.
``(2) Prohibitions.--
``(A) Generally.--No person shall serve as Director
or Deputy Director while serving in any other position
in the Federal Government.
``(B) Prohibition on political campaigning.--Any
officer or employee of the Office who is appointed to
that position by the President, by and with the advice
and consent of the Senate, may not participate in
Federal election campaign activities, except that such
officer or employee is not prohibited by this
subparagraph from making contributions to individual
candidates.
``(b) Prohibition on the Use of Funds for Political Campaigns or
Ballot Initiatives.--No funds authorized under this chapter may be
obligated for the purpose of influencing any Federal, State, or local
election or ballot initiative.
``(c) Personnel Detailed to Office.--
``(1) Evaluations.--Notwithstanding any provision of
chapter 43 of title 5, the Director shall perform the
evaluation of the performance of any employee detailed to the
Office for purposes of the applicable performance appraisal
system established under such chapter for any rating period, or
part thereof, that such employee is detailed to the Office.
``(2) Compensation.--
``(A) Bonus payments.--Subject to the availability
of appropriations, the Director may provide periodic
bonus payments to any employee detailed to the Office.
``(B) Restrictions.--An amount paid under this
paragraph to an employee for any period--
``(i) shall not be greater than 20 percent
of the basic pay paid or payable to such
employee for such period; and
``(ii) shall be in addition to the basic
pay of such employee.
``(C) Aggregate amount.--The aggregate amount paid
during any fiscal year to an employee detailed to the
Office as basic pay, awards, bonuses, and other
compensation shall not exceed the annual rate payable
at the end of such fiscal year for positions at level
III of the Executive Schedule.
``(d) Congressional Access to Information.--The location of the
Office in the Executive Office of the President shall not be construed
as affecting access by Congress, or any committee of the House of
Representatives or the Senate, to any--
``(1) information, document, or study in the possession of,
or conducted by or at the direction of the Director; or
``(2) personnel of the Office.
``(e) Other Authorities of the Director.--In carrying out this
chapter, the Director may--
``(1) use for administrative purposes, on a reimbursable
basis, the available services, equipment, personnel, and
facilities of Federal, State, and local agencies;
``(2) procure the services of experts and consultants in
accordance with section 3109 of title 5 relating to
appointments in the Federal Service, at rates of compensation
for individuals not to exceed the daily equivalent of the rate
of pay payable under level IV of the Executive Schedule under
section 5311 of such title; and
``(3) use the mails in the same manner as any other agency.
``(f) General Services Administration.--The Administrator of
General Services shall provide to the Director, on a reimbursable
basis, such administrative support services as the Director may
request.
``Sec. 1004. National drug control program budget
``(a) Budget Recommendations.--Not later than July 1 of each year,
the Director shall provide to the head of each National Drug Control
Program Agency budget recommendations, including requests for specific
initiatives that are consistent with the priorities of the President
under the National Drug Control Strategy, which shall--
``(1) apply to the budget for the next fiscal year
scheduled for formulation under chapter 11, and each of the 4
subsequent fiscal years; and
``(2) address funding priorities developed in the National
Drug Control Strategy.
``(b) Responsibilities of National Drug Control Program Agencies.--
``(1) In general.--For each fiscal year, the head of each
National Drug Control Program Agency shall transmit to the
Director a copy of the proposed drug control budget request of
such agency at the same time as that budget request is
submitted to their superiors (and before submission to the
Office of Management and Budget) in the preparation of the
budget of the President submitted to Congress under section
1105(a).
``(2) Submission of drug control budget requests.--The head
of each National Drug Control Program Agency shall ensure
timely development and submission to the Director of each
proposed drug control budget request transmitted pursuant to
this subsection, in such format as may be designated by the
Director with the concurrence of the Director of the Office of
Management and Budget.
``(3) Content of drug control budget requests.--A drug
control budget request submitted by the head of a National Drug
Control Program Agency under this subsection shall include all
requests for funds for any drug control activity undertaken by
such agency, including demand reduction, supply reduction, and
State, local, and Tribal affairs, including any drug law
enforcement activities. If an activity has both drug control
and nondrug control purposes or applications, such agency shall
estimate by a documented calculation the total funds requested
for that activity that would be used for drug control, and
shall set forth in its request the basis and method for making
the estimate.
``(c) Review and Certification of Budget Requests and Budget
Submissions of National Drug Control Program Agencies.--
``(1) In general.--The Director shall review each drug
control budget request submitted to the Director under
subsection (b).
``(2) Review of budget requests.--
``(A) Inadequate requests.--If the Director
concludes that a budget request submitted under
subsection (b) is inadequate, in whole or in part, to
implement the objectives of the National Drug Control
Strategy with respect to the agency or program at issue
for the year for which the request is submitted, the
Director shall submit to the head of the applicable
National Drug Control Program Agency a written
description identifying the funding levels and specific
initiatives that would, in the determination of the
Director, make the request adequate to implement those
objectives.
``(B) Adequate requests.--If the Director concludes
that a budget request submitted under subsection (b) is
adequate to implement the objectives of the National
Drug Control Strategy with respect to the agency or
program at issue for the year for which the request is
submitted, the Director shall submit to the head of the
applicable National Drug Control Program Agency a
written statement confirming the adequacy of the
request.
``(C) Record.--The Director shall maintain a record
of each description submitted under subparagraph (A)
and each statement submitted under subparagraph (B).
``(3) Specific requests.--The Director shall not confirm
the adequacy of any budget request that requests a level of
funding that will not enable achievement of the goals of the
National Drug Control Strategy, including--
``(A) requests funding for Federal law enforcement
activities that do not adequately compensate for
transfers of drug enforcement resources and personnel
to law enforcement and investigation activities;
``(B) requests funding for law enforcement
activities on the borders of the United States that do
not adequately direct resources to drug interdiction
and enforcement;
``(C) requests funding for substance use disorder
treatment activities that do not provide adequate
results and accountability measures;
``(D) requests funding for substance use disorder
treatment activities that do not adequately support and
enhance Federal substance use disorder programs and
capacity; and
``(E) requests funding for the operations and
management of the Department of Homeland Security that
does not include a specific request for funds for the
Office of Counternarcotics Enforcement to carry out its
responsibilities under section 878 of the Homeland
Security Act of 2002 (6 U.S.C. 458).
``(4) Agency response.--
``(A) In general.--The head of a National Drug
Control Program Agency that receives a description
under paragraph (2)(A) shall include the funding levels
and initiatives described by the Director in the budget
submission for that agency to the Office of Management
and Budget.
``(B) Impact statement.--The head of a National
Drug Control Program Agency that has altered its budget
submission under this paragraph shall include as an
appendix to the budget submission for that agency to
the Office of Management and Budget an impact statement
that summarizes--
``(i) the changes made to the budget under
this paragraph; and
``(ii) the impact of those changes on the
ability of that agency to perform its other
responsibilities, including any impact on
specific missions or programs of the agency.
``(C) Congressional notification.--The head of a
National Drug Control Program Agency shall submit a
copy of any impact statement under subparagraph (B) to
the Senate, the House of Representatives, and the
appropriate congressional committees, at the time the
budget for that agency is submitted to Congress under
section 1105(a).
``(5) Certification of budget submissions.--
``(A) In general.--At the time the head of a
National Drug Control Program Agency submits its budget
request to the Office of Management and Budget, the
head of the National Drug Control Program Agency shall
submit a copy of the budget request to the Director.
``(B) Review and certification of submissions.--The
Director shall review each budget submission submitted
under subparagraph (A) and submit to the appropriate
congressional committees one of the following:
``(i) A written certification of the budget
submission for the agency indicating such
request fully funds the National Drug Control
Programs as necessary to achieve the goals of
the National Drug Control Strategy, including a
written statement explaining the basis for the
determination that the budget submission
provides sufficient resources for the agency to
achieve the goals of the Strategy.
``(ii) A written certification of the
budget submission for the agency indicating
such request partially funds the National Drug
Control Programs as necessary to achieve the
goals of the Strategy, including a written
statement explaining the basis for the
determination to certify the budget submission
and identifying the level of funding sufficient
to achieve the goals of the Strategy.
``(iii) A written decertification of the
budget submission for the agency indicating the
Director is unable to determine whether such
budget submission for the agency fully funds or
partially funds the National Drug Control
Programs as necessary to achieve the goals of
the National Drug Control Strategy, including a
written statement identifying the additional
information necessary for the Director to make
a determination on such budget submission and
the level of funding sufficient to achieve the
goals of the Strategy.
``(iv) A written decertification of the
budget submission for the agency indicating
that such budget is insufficient to fund the
National Drug Control Programs as necessary to
achieve the goals of the Strategy, including a
written statement explaining the basis for the
determination that the budget is insufficient
and identifying the level of funding sufficient
to achieve the goals of the Strategy.
``(d) National Drug Control Program Budget Proposal.--For each
fiscal year, following the transmission of proposed drug control budget
requests to the Director under subsection (b), the Director shall, in
consultation with the head of each National Drug Control Program Agency
and the head of each major national organization that represents law
enforcement officers, agencies, or associations--
``(1) develop a consolidated National Drug Control Program
budget proposal designed to implement the National Drug Control
Strategy and to inform Congress and the public about the total
amount proposed to be spent on all supply reduction, demand
reduction, State, local, and Tribal affairs, including any drug
law enforcement, and other drug control activities by the
Federal Government, which shall conform to the content
requirements set forth in subsection (b)(3) and include--
``(A) for each National Drug Control Program
Agency, a list of whether the funding level is full,
partial, or insufficient to achieve the goals of the
National Drug Control Strategy or whether the Director
is unable to make such determination;
``(B) a statement describing the extent to which
any budget of a National Drug Control Program Agency
with less than full funding hinders progress on
achieving the goals of the National Drug Control
Strategy; and
``(C) alternative funding structures that could
improve progress on achieving the goals of the National
Drug Control Strategy; and
``(2) submit the consolidated budget proposal to the
President and Congress.
``(e) Budget Estimate or Request Submission to Congress.--Whenever
the Director submits any budget estimate or request to the President or
the Office of Management and Budget, the Director shall concurrently
transmit to the appropriate congressional committees a detailed
statement of the budgetary needs of the Office to execute its mission
based on the good-faith assessment of the Director.
``(f) Reprogramming and Transfer Requests.--
``(1) In general.--No National Drug Control Program Agency
shall submit to Congress a reprogramming or transfer request
with respect to any amount of appropriated funds in an amount
exceeding $1 million that is included in the National Drug
Control Program budget unless the request has been approved by
the Director. If the Director has not responded to a request
for reprogramming subject to this paragraph within 30 days
after receiving notice of the request having been made, the
request shall be deemed approved by the Director under this
paragraph and forwarded to Congress.
``(2) Appeal.--The head of any National Drug Control
Program Agency may appeal to the President any disapproval by
the Director of a reprogramming or transfer request under this
subsection.
``Sec. 1005. National drug control strategy
``(a) In General.--
``(1) Statement of drug policy priorities.--The Director
shall release a statement of drug control policy priorities in
the calendar year of a Presidential inauguration following the
inauguration but not later than April 1.
``(2) National drug control strategy submitted by the
president.--Not later than the first Monday in February
following the year in which the term of the President
commences, the President shall submit to Congress a National
Drug Control Strategy.
``(b) Development of the National Drug Control Strategy.--
``(1) Promulgation.--The Director shall promulgate the
National Drug Control Strategy, which shall set forth a
comprehensive plan to reduce illicit drug use and the
consequences of such illicit drug use in the United States by
limiting the availability of and reducing the demand for
illegal drugs and promoting prevention, early intervention,
treatment, and recovery support for individuals with substance
use disorders.
``(2) State and local commitment.--The Director shall seek
the support and commitment of State, local, and Tribal
officials in the formulation and implementation of the National
Drug Control Strategy.
``(3) Strategy based on evidence.--The Director shall
ensure the National Drug Control Strategy is based on the best
available medical and scientific evidence regarding the
policies that are most effective in reducing the demand for and
supply of illegal drugs.
``(4) Process for development and submission of national
drug control strategy.--In developing and effectively
implementing the National Drug Control Strategy, the Director--
``(A) shall consult with--
``(i) the heads of the National Drug
Control Program Agencies;
``(ii) each Coordinator established under
this chapter;
``(iii) the Interdiction Committee, the
Treatment Committee, and the Emerging Threats
Task Force;
``(iv) the appropriate congressional
committees and any other committee of
jurisdiction;
``(v) State, local, and Tribal officials;
``(vi) private citizens and organizations,
including community and faith-based
organizations, with experience and expertise in
demand reduction;
``(vii) private citizens and organizations
with experience and expertise in supply
reduction; and
``(viii) appropriate representatives of
foreign governments; and
``(B) in satisfying the requirements of
subparagraph (A), shall ensure, to the maximum extent
possible, that State, local, and Tribal officials and
relevant private organizations commit to support and
take steps to achieve the goals and objectives of the
National Drug Control Strategy.
``(c) Contents of the National Drug Control Strategy.--
``(1) In general.--The National Drug Control Strategy
submitted under subsection (a)(2) shall include the following:
``(A) A description of the current prevalence of
illicit drug use in the United States, including both
the availability of illicit drugs and the prevalence of
substance use disorders, which shall include the
following:
``(i) Such description for the previous 3
years for any drug identified as an emerging
threat under section 1009 and any other illicit
drug identified by the Director as having a
significant impact on the prevalence of illicit
drug use.
``(ii) A summary of the data and trends
presented in the Drug Control Data Dashboard
required under section 1013.
``(B) A mission statement detailing the major
functions of the National Drug Control Program.
``(C) A list of comprehensive, research-based,
long-range, quantifiable goals for reducing illicit
drug use, including--
``(i) the percentage of the total flow of
illicit drugs to be interdicted during the time
period covered by the Strategy; and
``(ii) the number of individuals to receive
substance use disorder treatment.
``(D) A description of how each goal established
under subparagraph (C) will be achieved, including for
each goal--
``(i) a list of each relevant National Drug
Control Program Agency and each such agency's
related programs, activities, and available
assets and the role of each such program,
activity, and asset in achieving such goal;
``(ii) a list of relevant stakeholders and
each such stakeholder's role in achieving such
goal;
``(iii) an estimate of Federal funding and
other resources needed to achieve such goal;
``(iv) a list of each existing or new
coordinating mechanism needed to achieve such
goal; and
``(v) a description of the Office's role in
facilitating the achievement of such goal.
``(E) For each year covered by the Strategy, a
performance evaluation plan for each goal established
under subparagraph (C) for each National Drug Control
Program Agency, including--
``(i) specific performance measures for
each National Drug Control Program Agency and
each such agency's related programs and
activities;
``(ii) annual and, to the extent
practicable, quarterly objectives and targets
for each performance measure; and
``(iii) an estimate of Federal funding and
other resources needed to achieve each
performance objective and target.
``(F) A list identifying existing data sources or a
description of data collection needed to evaluate
performance, including a description of how the
Director will obtain such data.
``(G) A list of any anticipated challenges to
achieving the National Drug Control Strategy goals and
planned actions to address such challenges.
``(H) A description of how each goal established
under subparagraph (C) was determined, including--
``(i) a description of each required
consultation and a description of how such
consultation was incorporated;
``(ii) data, research, or other information
used to inform the determination to establish
the goal; and
``(iii) for any goal established under
subparagraph (C)(i), a statement of whether the
goal will be adequate to disrupt drug
trafficking organizations that supply the
majority of foreign-sourced illicit drugs
trafficked into the United States.
``(I) A 5-year projection for program and budget
priorities.
``(J) A review of international, State, local, and
private sector drug control activities to ensure that
the United States pursues coordinated and effective
drug control at all levels of government.
``(K) Such statistical data and information as the
Director considers appropriate to demonstrate and
assess trends relating to illicit drug use, the effects
and consequences of illicit drug use (including the
effects on children), supply reduction, demand
reduction, drug-related law enforcement, and the
implementation of the National Drug Control Strategy.
``(2) Additional strategies.--
``(A) In general.--The Director shall include in
the National Drug Control Strategy the additional
strategies described under this paragraph and shall
comply with the following:
``(i) Provide a copy of the additional
strategies to the appropriate congressional
committees and to the Committee on Armed
Services and the Committee on Homeland Security
of the House of Representatives, and the
Committee on Homeland Security and Governmental
Affairs and the Committee on Armed Services of
the Senate.
``(ii) Issue the additional strategies in
consultation with the head of each relevant
National Drug Control Program Agency, any
relevant official of a State, local, or Tribal
government, and the government of other
relevant countries.
``(iii) Not change any existing agency
authority or construe any strategy described
under this paragraph to amend or modify any law
governing interagency relationship but may
include recommendations about changes to such
authority or law.
``(iv) Present separately from the rest of
any strategy described under this paragraph any
information classified under criteria
established by an Executive order, or whose
public disclosure, as determined by the
Director or the head of any relevant National
Drug Control Program Agency, would be
detrimental to the law enforcement or national
security activities of any Federal, State,
local, or Tribal agency.
``(B) Requirement for southwest border
counternarcotics.--
``(i) Purposes.--The Southwest Border
Counternarcotics Strategy shall--
``(I) set forth the Government's
strategy for preventing the illegal
trafficking of drugs across the
international border between the United
States and Mexico, including through
ports of entry and between ports of
entry on that border;
``(II) state the specific roles and
responsibilities of the relevant
National Drug Control Program Agencies
for implementing that strategy; and
``(III) identify the specific
resources required to enable the
relevant National Drug Control Program
Agencies to implement that strategy.
``(ii) Specific content related to drug
tunnels between the united states and mexico.--
The Southwest Border Counternarcotics Strategy
shall include--
``(I) a strategy to end the
construction and use of tunnels and
subterranean passages that cross the
international border between the United
States and Mexico for the purpose of
illegal trafficking of drugs across
such border; and
``(II) recommendations for criminal
penalties for persons who construct or
use such a tunnel or subterranean
passage for such a purpose.
``(C) Requirement for northern border
counternarcotics strategy.--
``(i) Purposes.--The Northern Border
Counternarcotics Strategy shall--
``(I) set forth the strategy of the
Federal Government for preventing the
illegal trafficking of drugs across the
international border between the United
States and Canada, including through
ports of entry and between ports of
entry on the border;
``(II) state the specific roles and
responsibilities of each relevant
National Drug Control Program Agency
for implementing the strategy;
``(III) identify the specific
resources required to enable the
relevant National Drug Control Program
Agencies to implement the strategy;
``(IV) be designed to promote, and
not hinder, legitimate trade and
travel; and
``(V) reflect the unique nature of
small communities along the
international border between the United
States and Canada, ongoing cooperation
and coordination with Canadian law,
enforcement authorities, and variations
in the volumes of vehicles and
pedestrians crossing through ports of
entry along the international border
between the United States and Canada.
``(ii) Specific content related to cross-
border indian reservations.--The Northern
Border Counternarcotics Strategy shall
include--
``(I) a strategy to end the illegal
trafficking of drugs to or through
Indian reservations on or near the
international border between the United
States and Canada; and
``(II) recommendations for
additional assistance, if any, needed
by Tribal law enforcement agencies
relating to the strategy, including an
evaluation of Federal technical and
financial assistance, infrastructure
capacity building, and interoperability
deficiencies.
``(3) Classified information.--Any contents of the National
Drug Control Strategy that involve information properly
classified under criteria established by an Executive order
shall be presented to Congress separately from the rest of the
National Drug Control Strategy.
``(4) Selection of data and information.--In selecting data
and information for inclusion in the Strategy, the Director
shall ensure--
``(A) the inclusion of data and information that
will permit analysis of current trends against
previously compiled data and information where the
Director believes such analysis enhances long-term
assessment of the National Drug Control Strategy; and
``(B) the inclusion of data and information to
permit a standardized and uniform assessment of the
effectiveness of drug treatment programs in the United
States.
``(d) Annual Performance Supplement.--Not later than the first
Monday in February of each year following the year in which the
National Drug Control Strategy is submitted pursuant to subsection
(a)(2), the Director shall submit to the appropriate congressional
committees a supplement to the Strategy that shall include--
``(1) annual and, to the extent practicable, quarterly
quantifiable and measurable objectives and specific targets to
accomplish long-term quantifiable goals specified in the
Strategy; and
``(2) for each year covered by the Strategy, a performance
evaluation plan for each goal listed in the Strategy for each
National Drug Control Program Agency, including--
``(A) specific performance measures for each
National Drug Control Program Agency and each such
agency's related programs and activities;
``(B) annual and, to the extent practicable,
quarterly objectives and targets for each performance
measure; and
``(C) an estimate of Federal funding and other
resources needed to achieve each performance objective
and target.
``(e) Submission of Revised Strategy.--
``(1) In general.--The President may submit to Congress a
revised National Drug Control Strategy that meets the
requirements of this section--
``(A) at any time, upon a determination of the
President, in consultation with the Director, that the
National Drug Control Strategy in effect is not
sufficiently effective; or
``(B) if a new President or Director takes office.
``(2) No submission.--In each year the President does not
submit a National Drug Control Strategy or a revised National
Drug Control Strategy, the Director shall evaluate the efficacy
and appropriateness of the goals of the National Drug Control
Strategy and include a statement affirming the adequacy of the
goals in the performance supplement under subsection (d).
``(f) Failure of President to Submit National Drug Control
Strategy.--If the President does not submit a National Drug Control
Strategy to Congress in accordance with subsection (a)(2), not later
than 5 days after the first Monday in February following the year in
which the term of the President commences, the President shall send a
notification to the appropriate congressional committees--
``(1) explaining why the Strategy was not submitted; and
``(2) specifying the date by which the Strategy will be
submitted.
``Sec. 1006. Development of an annual national drug control assessment
``(a) Timing.--Not later than the first Monday in February of each
year, the Director shall submit to the President, Congress, and the
appropriate congressional committees, a report assessing the progress
of each National Drug Control Program Agency toward achieving each
goal, objective, and target contained in the National Drug Control
Strategy applicable to the prior fiscal year.
``(b) Process for Development of the Annual Assessment.--Not later
than November 1 of each year, the head of each National Drug Control
Program Agency shall submit, in accordance with guidance issued by the
Director, to the Director an evaluation of progress by the agency with
respect to the National Drug Control Strategy goals using the
performance measures for the agency developed under this chapter,
including progress with respect to--
``(1) success in achieving the goals of the National Drug
Control Strategy;
``(2) success in reducing domestic and foreign sources of
illegal drugs;
``(3) success in expanding access to and increasing the
effectiveness of substance use disorder treatment;
``(4) success in protecting the borders of the United
States (and in particular the Southwestern border of the United
States) from penetration by illegal narcotics;
``(5) success in reducing crime associated with drug use in
the United States;
``(6) success in reducing the negative health and social
consequences of drug use in the United States; and
``(7) implementation of substance use disorder treatment
and prevention programs in the United States and improvements
in the adequacy and effectiveness of such programs.
``(c) Contents of the Annual Assessment.--The Director shall
include in the annual assessment required under subsection (a)--
``(1) a summary of each evaluation received by the Director
under subsection (b);
``(2) a summary of the progress of each National Drug
Control Program Agency toward the National Drug Control
Strategy goals of the agency using the performance measures for
the agency developed under this chapter;
``(3) an assessment of the effectiveness of each National
Drug Control Program Agency and program in achieving the
National Drug Control Strategy for the previous year, including
a specific evaluation of whether the applicable goals,
measures, objectives, and targets for the previous year were
met;
``(4) for each National Drug Control Program Agency that
administers grant programs, an evaluation of the effectiveness
of each grant program, including an accounting of the funds
disbursed by the program in the prior year and a summary of how
those funds were used by the grantees and sub-grantees during
that period;
``(5) a detailed accounting of the amount of funds
obligated by each National Drug Control Program Agency in
carrying out the responsibilities of that agency under the
Strategy;
``(6) an assessment of the effectiveness of any Emerging
Threat Response Plan in effect for the previous year, including
a specific evaluation of whether the objectives and targets
were met and reasons for the success or failure of the previous
year's plan;
``(7) a detailed accounting of the amount of funds
obligated during the previous fiscal year for carrying out the
campaign under section 1009(d), including each recipient of
funds, the purpose of each expenditure, the amount of each
expenditure, any available outcome information, and any other
information necessary to provide a complete accounting of the
funds expended; and
``(8) the assessments required under this subsection shall
be based on the Performance Measurement System describe in
subsection (d).
``(d) Performance Measurement System.--The Director shall include
in the annual assessment required under subsection (a) a national drug
control performance measurement system, that--
``(1) develops annual, 2-year, and 5-year performance
measures, objectives, and targets for each National Drug
Control Strategy goal and objective established for reducing
drug use, availability, and the consequences of drug use;
``(2) describes the sources of information and data that
will be used for each performance measure incorporated into the
performance measurement system;
``(3) identifies major programs and activities of the
National Drug Control Program Agencies that support the goals
and annual objectives of the National Drug Control Strategy;
``(4) evaluates the contribution of demand reduction and
supply reduction activities implemented by each National Drug
Control Program Agency in support of the National Drug Control
Strategy;
``(5) monitors consistency between the drug-related goals,
measures, targets, and objectives of the National Drug Control
Program Agencies and ensures that each agency's goals and
budgets support, and are fully consistent with, the National
Drug Control Strategy; and
``(6) coordinates the development and implementation of
national drug control data collection and reporting systems to
support policy formulation and performance measurement,
including an assessment of--
``(A) the quality of current drug use measurement
instruments and techniques to measure supply reduction
and demand reduction activities;
``(B) the adequacy of the coverage of existing
national drug use measurement instruments and
techniques to measure the illicit drug user population
and groups that are at risk for illicit drug use;
``(C) the adequacy of the coverage of existing
national treatment outcome monitoring systems to
measure the effectiveness of substance use disorder
treatment in reducing illicit drug use and criminal
behavior during and after the completion of substance
use disorder treatment; and
``(D) the actions the Director shall take to
correct any deficiencies and limitations identified
pursuant to subparagraphs (A), (B), and (C).
``(e) Modifications.--A description of any modifications made
during the preceding year to the national drug performance measurement
system described in subsection (d) shall be included in each report
submitted under subsection (a).
``(f) Annual Report on Consultation.--The Director shall include in
the annual assessment required under subsection (a)--
``(1) a detailed description of how the Office has
consulted with and assisted State, local, and Tribal
governments with respect to the formulation and implementation
of the National Drug Control Strategy and other relevant
issues; and
``(2) a general review of the status of, and trends in,
demand reduction activities by private sector entities and
community-based organizations, including faith-based
organizations, to determine their effectiveness and the extent
of cooperation, coordination, and mutual support between such
entities and organizations and Federal, State, local, and
Tribal government agencies.
``(g) Performance-Budget Coordinator.--
``(1) Designation.--The Director shall designate or appoint
a United States Performance-Budget Coordinator to--
``(A) ensure the Director has sufficient
information necessary to analyze the performance of
each National Drug Control Program Agency, the impact
Federal funding has had on the goals in the Strategy,
and the likely contributions to the goals of the
Strategy based on funding levels of each National Drug
Control Program Agency, to make an independent
assessment of the budget request of each agency under
section 1004;
``(B) advise the Director on agency budgets,
performance measures and targets, and additional data
and research needed to make informed policy decisions
under sections 1004 and 1005; and
``(C) other duties as may be determined by the
Director with respect to measuring or assessing
performance or agency budgets.
``(2) Determination of position.--The Director shall
determine whether the coordinator position is a noncareer
appointee in the Senior Executive Service or a career appointee
at the GS-15 level (or equivalent) or above.
``Sec. 1007. Monitoring and evaluation of national drug control program
``(a) In General.--The Director shall monitor implementation of the
National Drug Control Program and the activities of the National Drug
Control Program Agencies in carrying out the goals and objectives of
the National Drug Control Strategy including--
``(1) conducting program and performance audits and
evaluations; and
``(2) requesting assistance from the Inspector General of
the relevant agency in such audits and evaluations.
``(b) Accounting of Funds Expended.--(1) Not later than February 1
of each year, in accordance with guidance issued by the Director, the
head of each National Drug Control Program Agency shall submit to the
Director a detailed accounting of all funds expended by the agency for
National Drug Control Program activities during the previous fiscal
year and shall ensure such detailed accounting is authenticated for the
previous fiscal year by the Inspector General for such agency prior to
the submission to the Director as frequently as determined by the
Inspector General but not less frequently that every 3 years.
``(2) The Director shall submit to Congress not later than April 1
of each year the information submitted to the Director under paragraph
(1).
``(c) Notification.--The Director shall notify any National Drug
Control Program Agency if its activities are not in compliance with the
responsibilities of the agency under the National Drug Control
Strategy, transmit a copy of each such notification to the President
and the appropriate congressional committees, and maintain a copy of
each such notification.
``(d) Recommendations.--The Director shall make such
recommendations to the President and the appropriate congressional
committees as the Director determines are appropriate regarding changes
in the organization, management, and budgets of the National Drug
Control Program Agencies, and changes in the allocation of personnel to
and within those agencies, to implement the policies, goals,
objectives, and priorities established under section 1002(c)(1) and the
National Drug Control Strategy.
``(e) Authorization, Development, and Implementation of a
Coordinated Tracking System.--
``(1) Establishment.--The Director shall establish a
coordinated tracking system of federally-funded initiatives and
grant programs which shall--
``(A) be the central repository of all drug control
grants;
``(B) identify duplication, overlap, or gaps in
funding to provide increased accountability of
federally-funded grants for substance use disorder
treatment, prevention, and enforcement;
``(C) identify impediments that applicants
currently have in the grant application process with
applicable agencies; and
``(D) be developed and maintained by the Office
with the support of designated National Drug Control
Program Agencies and any other agency determined by the
Director.
``(2) Performance metrics.--The Director shall identify
metrics and achievable goals for grant recipients in
furtherance of the Strategy. Such metrics shall be used to
measure how effective each federally funded initiative is in
achieving the objectives of the Strategy and to enable
comparisons of federally funded initiatives to identify those
that are the most cost effective.
``(3) Grant application standardization.--To reduce the
administrative burden on grant applicants and improve oversight
of Federal funds, the Director, in consultation with the head
of each National Drug Control Program Agency, shall develop a
plan for coordinating and standardizing drug control grant
application processes and develop a joint application to be
used by all National Drug Control Program Agencies.
``(4) Central portal.--The Director shall maintain on the
public, electronic portal of the Office a list all drug control
grant programs available in a central location. The head of
each National Drug Control Program Agency shall provide a
complete list of all drug control program grant programs to the
Director and annually update such list.
``(5) Report to congress.--The Director shall include in
the assessment submitted to Congress under section 1006 an
assessment on progress under this section.
``Sec. 1008. Coordination and oversight of the national drug control
program
``(a) In General.--The Director shall coordinate and oversee the
implementation by the National Drug Control Program Agencies of the
policies, goals, objectives, and priorities established under section
1002(c)(1) and the fulfillment of the responsibilities of such agencies
under the National Drug Control Strategy and make recommendations to
National Drug Control Program Agency heads with respect to
implementation of National Drug Control Programs.
``(b) Detailing Employees to Other Agencies.--
``(1) Request.--The Director may request the head of an
agency or program of the Federal Government to place agency
personnel who are engaged in drug control activities on
temporary detail to another agency in order to implement the
National Drug Control Strategy.
``(2) Agency compliance.--The head of the agency shall
comply with any request made under paragraph (1).
``(3) Maximum number of detailees.--The maximum number of
personnel who may be detailed to another agency (including the
Office) under this subsection during any fiscal year is--
``(A) for the Department of Defense, 50; and
``(B) for any other agency, 10.
``(c) Directing Federal Funding.--The Director may transfer funds
made available to a National Drug Control Program Agency for National
Drug Control Strategy programs and activities to another account within
such agency or to another National Drug Control Program Agency for
National Drug Control Strategy programs and activities, except that--
``(1) the authority under this subsection may be limited in
an annual appropriations Act or other provision of Federal law;
``(2) the Director may exercise the authority under this
subsection only with the concurrence of the head of each
affected agency;
``(3) in the case of an interagency transfer, the total
amount of transfers under this subsection may not exceed 3
percent of the total amount of funds made available for
National Drug Control Strategy programs and activities to the
agency from which those funds are to be transferred;
``(4) funds transferred to an agency under this subsection
may only be used to increase the funding for programs or
activities authorized by law;
``(5) the Director shall--
``(A) submit to the appropriate congressional
committees and any other applicable committee of
jurisdiction, a reprogramming or transfer request in
advance of any transfer under this subsection in
accordance with the regulations of each affected
agency; and
``(B) annually submit to the appropriate
congressional committees a report describing the effect
of all transfers of funds made pursuant to this
subsection or section 1004(f) during the 12-month
period preceding the date on which the report is
submitted; and
``(6) funds may only be used for--
``(A) expansion of demand reduction activities;
``(B) interdiction of illicit drugs on the high
seas, in United States territorial waters, and at
United States ports of entry by officers and employees
of National Drug Control Program Agencies and domestic
and foreign law enforcement officers;
``(C) accurate assessment and monitoring of
international drug production and interdiction programs
and policies;
``(D) activities to facilitate and enhance the
sharing of domestic and foreign intelligence
information among National Drug Control Program
Agencies related to the production and trafficking of
drugs in the United States and foreign countries;
``(E) activities to prevent the diversion of
prescription drugs for illicit use; and
``(F) research related to any of these activities.
``(d) Directing Federal Funding to Respond to Emerging Threats.--
``(1) In general.--The Director may transfer funds made
available to a National Drug Control Program Agency for
National Drug Control Strategy programs and activities to
another account within such agency or to another National Drug
Control Program Agency for National Drug Control Strategy
programs and activities to implement the provisions of a plan
developed under section 1009, except that--
``(A) the authority under this subsection may be
limited in an annual appropriations Act or other
provision of Federal law;
``(B) the Director may exercise the authority under
this subsection only with the concurrence of the head
of each affected agency;
``(C) in the case of an interagency transfer, the
total amount of transfers under this subsection may not
exceed 10 percent of the total amount of funds made
available for National Drug Control Strategy programs
and activities to the agency from which those funds are
to be transferred;
``(D) funds transferred to an agency under this
subsection may only be used to increase the funding for
programs or activities authorized by law;
``(E) no transfer of funds under this subsection
may result in a reduction in total Federal expenditures
for substance use disorder treatment;
``(F) the Director shall--
``(i) submit to the appropriate
congressional committees and any other
applicable committee of jurisdiction, a
reprogramming or transfer request in advance of
any transfer under this subsection in
accordance with the regulations of each
affected agency; and
``(ii) annually submit to the appropriate
congressional committees a report describing
the effect of all transfers of funds made
pursuant to this subsection or section 1004(f)
during the 12-month period preceding the date
on which the report is submitted; and
``(G) funds may only be used for--
``(i) expansion of demand reduction
activities;
``(ii) interdiction of illicit drugs on the
high seas, in United States territorial waters,
and at United States ports of entry by officers
and employees of National Drug Control Program
Agencies and domestic and foreign law
enforcement officers;
``(iii) accurate assessment and monitoring
of international drug production and
interdiction programs and policies;
``(iv) activities to facilitate and enhance
the sharing of domestic and foreign
intelligence information among National Drug
Control Program Agencies related to the
production and trafficking of drugs in the
United States and foreign countries;
``(v) activities to prevent the diversion
of prescription drugs for illicit use; and
``(vi) research related to any of these
activities.
``(2) Inadequacy of transfer.--In the event the authority
under this subsection is inadequate to implement the provisions
of a plan developed under section 1009, the Director shall
submit a request for funding to the appropriate congressional
committees within 30 days after the date on which the Director
determines there is a need for additional funding.
``(e) Fund Control Notices.--
``(1) In general.--The Director may issue to the head of a
National Drug Control Program Agency a fund control notice to
ensure compliance with the National Drug Control Program
Strategy. A fund control notice may direct that all or part of
an amount appropriated to the National Drug Control Program
Agency account be obligated by--
``(A) months, fiscal year quarters, or other time
periods; and
``(B) activities, functions, projects, or object
classes.
``(2) Unauthorized obligation or expenditure prohibited.--
An officer or employee of a National Drug Control Program
Agency shall not make or authorize an expenditure or obligation
contrary to a fund control notice issued by the Director.
``(3) Disciplinary action for violation.--In the case of a
violation of paragraph (2) by an officer or employee of a
National Drug Control Program Agency, the head of the agency,
upon the request of and in consultation with the Director, may
subject the officer or employee to appropriate administrative
discipline, including, when circumstances warrant, suspension
from duty without pay or removal from office.
``(4) Congressional notice.--Not later than 5 days after
issuance of a fund control notice, the Director shall submit a
copy of such fund control notice to the appropriate
congressional committees and make such notice publicly
available.
``(5) Restrictions.--The Director may not issue a fund
control notice to direct that all or part of an amount
appropriated to the National Drug Control Program Agency
account be obligated, modified, or altered in any manner
contrary, in whole or in part, to a specific appropriation or
statute.
``(f) Exclusions.--The authorities described under subsections (c),
(d), and (e) do not apply to any program under subchapter II or III.
``(g) Foreign Assistance Act Participation.--The Director may
participate in the drug certification process pursuant to section 490
of the Foreign Assistance Act of 1961 (22 U.S.C. 2291j) and section 706
of the Department of State Authorization Act for Fiscal Year 2003 (22
U.S.C. 229j-l).
``(h) Certifications of Policy Changes to Director.--
``(1) In general.--Subject to paragraph (2), the head of a
National Drug Control Program Agency shall, unless exigent
circumstances require otherwise, notify the Director in writing
regarding any proposed change in policies relating to the
activities of that agency under the National Drug Control
Program prior to implementation of such change. The Director
shall promptly review such proposed change and certify to the
head of that agency in writing whether such change is
consistent with the National Drug Control Strategy.
``(2) Exception.--If prior notice of a proposed change
under paragraph (1) is not practicable--
``(A) the head of the National Drug Control Program
Agency shall notify the Director of the proposed change
as soon as practicable; and
``(B) upon such notification, the Director shall
review the change and certify to the head of that
agency in writing whether the change is consistent with
the National Drug Control Strategy.
``(i) Work in Conjunction With Assistant for National Security
Affairs.--The Director shall, in any matter affecting national security
interests, work in conjunction with the Assistant to the President for
National Security Affairs.
``(j) Authorities Not Derogated.--Nothing in this chapter shall be
construed as derogating the authorities and responsibilities of the
head of any agency, the Director of National Intelligence, or the
Director of the Central Intelligence Agency contained in the National
Security Act of 1947 (50 U.S.C. 401 et seq.), the Central Intelligence
Agency Act of 1949 (50 U.S.C. 403a et seq.), or any other law.
``Sec. 1009. Emerging threats task force, plan, campaign
``(a) Emerging Threats Task Force.--
``(1) Emerging and continuing threats coordinator.--The
Director shall designate or appoint a United States Emerging
and Continuing Threats Coordinator to perform the duties of
that position described in this section and such other duties
as may be determined by the Director. The Director shall
determine whether the coordinator position is a noncareer
appointee in the Senior Executive Service or a career appointee
at the GS-15 level (or equivalent) or above.
``(2) Establishment and monitoring.--The Emerging and
Continuing Threats Coordinator (referred to in this section as
the `Coordinator') shall monitor evolving and emerging drug
threats in the United States and shall serve as Chair of an
Emerging Threats Task Force (in this section, referred to as
the `task force'). The Director shall appoint other members of
the task force, which shall include--
``(A) representatives from National Drug Control
Program Agencies or other agencies;
``(B) representatives from State, local, and Tribal
governments;
``(C) the Director of the National Drug Control
Fusion Center established in section 1013; and
``(D) representatives from other entities as
determined to be necessary by the Director.
``(3) Information review and sharing.--
``(A) In general.--The task force shall disseminate
and facilitate the sharing with Federal, State, local,
and Tribal officials and other entities as determined
by the Director of pertinent information and data
relating to the following:
``(i) Recent trends in drug supply and
demand.
``(ii) Fatal and nonfatal overdoses.
``(iii) Demand for and availability of
evidence-based substance use disorder
treatment, including the extent of the unmet
treatment need, and treatment admission trends.
``(iv) Recent trends in drug interdiction,
supply, and demand from State, local, and
Tribal law enforcement agencies.
``(v) Other subject matter as determined
necessary by the Director.
``(B) Contract, agreement, and other authority.--
The Director may award contracts, enter into
interagency agreements, manage individual projects, and
conduct other activities in support of the
identification of emerging drug threats and in support
of the development, implementation, and assessment of
any Emerging Threat Response Plan.
``(C) Data analysis activities.--In support of the
task force, the National Drug Control Fusion Center is
authorized to conduct and provide to the task force the
results of data analysis activities that the task force
requests to aid in their review of recent trends in the
data disseminated under subparagraph (A).
``(4) Criteria to identify emerging drug threats.--Not
later than 60 days after the date on which a task force first
meets, the task force shall develop and recommend to the
Director criteria to be used to identify an emerging drug
threat or the termination of an emerging drug threat
designation based on information gathered by the task force in
paragraph (2), statistical data, and other evidence.
``(5) Meetings.--The task force shall meet in person not
less frequently than quarterly and at additional meetings if
determined to be necessary by and at the call of the Chair to--
``(A) identify and discuss evolving and emerging
drug trends in the United States using the criteria
established in paragraph (3);
``(B) assist in the formulation of any plan
described in subsection (c);
``(C) oversee implementation of the plan described
in subsection (c); and
``(D) provide such other advice to the Coordinator
and Director concerning strategy and policies for
emerging drug threats and trends as the task force
determines to be appropriate.
``(b) Designation.--
``(1) In general.--The Director, in consultation with the
Coordinator, the task force, and the head of each National Drug
Control Program Agency, may designate an emerging drug threat
in the United States.
``(2) Standards for designation.--The Director, in
consultation with the Coordinator, shall promulgate and make
publicly available standards by which a designation under
paragraph (1) and the termination of such designation may be
made. In developing such standards, the Director shall consider
the recommendations of the task force and other criteria the
Director considers to be appropriate.
``(3) Public statement required.--The Director shall
publish a public written statement on the portal of the Office
explaining the designation of an emerging drug threat or the
termination of such designation and shall notify the
appropriate congressional committees of the availability of
such statement when a designation or termination of such
designation has been made.
``(c) Plan.--
``(1) Public availability of plan.--Not later than 60 days
after making a designation under subsection (b), the Director
shall publish and make publicly available an Emerging Threat
Response Plan and notify the President and the appropriate
congressional committees of such plan's availability.
``(2) Timing.--Not less frequently than every 90 days after
the date on which the plan is published under paragraph (1),
the Director shall update the plan and report on implementation
of the plan, until the Director issues the public statement
required under subsection (b)(3) to terminate the emerging drug
threat designation.
``(3) Contents of an emerging threat response plan.--The
Director shall include in the plan--
``(A) a comprehensive strategic assessment of the
emerging drug threat, including the current
availability of, demand for, and effectiveness of
evidence-based prevention, treatment, and enforcement
programs and efforts to respond to the emerging drug
threat;
``(B) comprehensive, research-based, long-range,
quantifiable goals for addressing the emerging drug
threat, including for reducing the supply of the drug
designated as the emerging drug threat and for
expanding the availability and effectiveness of
evidence-based substance use disorder treatment and
prevention programs to reduce the demand for the
emerging drug threat;
``(C) performance measures pertaining to the plan's
goals, including quantifiable and measurable objectives
and specific targets;
``(D) the level of funding needed to implement the
plan, including whether funding is available to be
reprogrammed or transferred to support implementation
of the plan or whether additional appropriations are
necessary to implement the plan;
``(E) an implementation strategy for the education
and public awareness campaign under subsection (d),
including goals as described under subparagraph (B) and
performance measures, objectives, and targets, as
described under subparagraph (C); and
``(F) any other information necessary to inform the
public of the status, progress, or response of an
emerging drug threat.
``(4) Implementation.--
``(A) In general.--Not later than 90 days after the
date on which a designation is made under subsection
(b), the Director, in consultation with the President,
the appropriate congressional committees, and the head
of each National Drug Control Program Agency, shall
issue guidance on implementation of the plan described
in this subsection to the National Drug Control Program
Agencies and any other relevant agency determined to be
necessary by the Director.
``(B) Coordinator's responsibilities.--The
Coordinator shall--
``(i) direct the implementation of the plan
among the agencies identified in the plan,
State, local, and Tribal governments, and other
relevant entities;
``(ii) facilitate information-sharing
between agencies identified in the plan, State,
local, and Tribal governments, and other
relevant entities; and
``(iii) monitor implementation of the plan
by coordinating the development and
implementation of collection and reporting
systems to support performance measurement and
adherence to the plan by agencies identified in
plan, where appropriate.
``(C) Reporting.--Not later than 180 days after the
date on which a designation is made under subsection
(b) and in accordance with paragraph (2)(C), the head
of each agency identified in the plan shall submit to
the Coordinator a report on implementation of the plan.
``(d) Education and Public Awareness Campaign for Emerging Drug
Threats.--
``(1) In general.--Not later than 90 days after the date on
which a designation is made under subsection (b), the Director
shall, to the extent feasible and appropriate, establish and
implement an evidence-based substance use prevention education
and public awareness campaign to inform the public about the
dangers of any drug designated as an emerging drug threat. Such
campaign shall--
``(A) educate the public about the dangers of such
drug, including patient and family education about the
characteristics and hazards of such drug and methods to
safeguard against such dangers, including the safe
disposal of such drug;
``(B) support evidence-based prevention programs
targeting audiences' attitudes, perceptions, and
beliefs concerning substance use and intentions to
initiate or continue such use;
``(C) increase awareness of the negative
consequences of drug use;
``(D) encourage individuals affected by substance
use disorders to seek treatment and provide such
individuals with information on how to recognize
addiction issues, what forms of evidence-based
treatment options are available, and how to access such
treatment; and
``(E) combat the stigma of addiction and substance
use disorders, including the stigma of treating such
disorders with medication-assisted treatment therapies.
``(2) Consultation.--For the planning of the campaign under
paragraph (1), the Director shall consult with--
``(A) the head of any appropriate National Drug
Control Program Agency to obtain advice on evidence-
based scientific information for policy, program
development, and evaluation;
``(B) experts in evidence-based media campaigns,
education, evaluation, and communication;
``(C) experts on the designated drug;
``(D) State, local, and Tribal government officials
and relevant agencies;
``(E) the public;
``(F) appropriate congressional committees; and
``(G) any other affected person, as determined by
the Director.
``(3) Gifts and donations.--
``(A) In general.--The Director may accept gifts
and donations (in cash or in kind, including voluntary
and uncompensated services or property), which shall be
available until expended, for the purpose of supporting
the education and public awareness campaign authorized
in this section, including the media campaign.
``(B) Ethics guidelines.--The Director shall
establish written guidelines setting forth the criteria
to be used in determining whether a gift or donation
should be declined under this section because the
acceptance of the gift or donation would--
``(i) reflect unfavorably upon the ability
of the Director or the Office, or any employee
of the Office, to carry out responsibilities or
official duties under this chapter in a fair
and objective manner; or
``(ii) compromise the integrity or the
appearance of integrity of programs or services
provided under this chapter or of any official
involved in those programs or services.
``(4) Implementation.--
``(A) In general.--For any campaign established
under this subsection, the Director shall ensure the
following:
``(i) Implementation is evidence-based,
meets accepted standards for public awareness
campaigns, and uses available resources in a
manner to make the most progress toward
achieving the goals identified in the Emerging
Threats Response Plan and the requirements of
paragraph (1).
``(ii) Information disseminated through the
campaign is accurate.
``(iii) The Director approves the strategy
of the campaign, all material distributed
through the campaign, and the use of any
Federal funds used for the campaign.
``(iv) The campaign is designed using
strategies found to be most effective at
achieving such goals and requirements of
paragraph (1), which may include--
``(I) a media campaign, as
described in subparagraph (B);
``(II) local, regional, or
population specific messaging;
``(III) establishing partnerships
and promoting coordination among
community stakeholders, including
public, nonprofit organizations, and
for profit entities;
``(IV) providing support, training,
and technical assistance to establish
and expand school and community
prevention programs;
``(V) creating websites to
publicize and disseminate information;
``(VI) conducting outreach and
providing educational resources for
parents;
``(VII) establishing State or
regional advisory councils to provide
input and recommendations to raise
awareness regarding the drug designated
as an emerging drug threat;
``(VIII) collaborating with law
enforcement; and
``(IX) support for school-based
public health education classes to
improve teen knowledge about the
effects of such designated drug.
``(B) Media campaign.--Any campaign implemented
under this subsection may include a media component,
which--
``(i) shall be designed to prevent the use
of the drug designated as an emerging drug
threat and to achieve the goals and
requirements of paragraph (1);
``(ii) shall be carried out through
competitively awarded contracts to entities
providing for the professional production and
design of such campaign; and
``(iii) may include the use of television,
radio, Internet, social media, and other
commercial marketing venues and may be targeted
to specific age groups based on peer-reviewed
social research.
``(C) Required notice for communication from the
office.--Any communication, including an advertisement,
paid for or otherwise disseminated by the Office
directly or through a contract awarded by the Office
shall include a prominent notice informing the audience
that the communication was paid for by of the Office.
``(5) Evaluation.--
``(A) Performance evaluation.--The Director shall
include an evaluation of the campaign in the annual
assessment under section 1006, which shall include the
following:
``(i) A performance evaluation of the
campaign, including progress toward meeting the
goals, objectives, measures, and targets
identified in the Emerging Threats Response
Plan.
``(ii) A description of all policies and
practices to eliminate the potential for waste,
fraud, abuse, and to ensure Federal funds are
used responsibly.
``(iii) A list of all contracts or other
agreements entered into to implement the
campaign.
``(iv) The results of any financial audit
of the campaign.
``(v) A description of any evidence used to
develop the campaign.
``(vi) The sources and amount of each gift
or donation accepted by the Office, and the
source and amount of each gift or donation
accepted by a contractor to be used in its
performance of a contract for the campaign.
``(B) Independent evaluation.--Not later than 180
days after establishing a campaign under paragraph (1)
and not less than frequently than every 2 years
thereafter, the Director shall--
``(i) designate an independent entity to
evaluate the effectiveness of the campaign with
meeting the goals established in the Emerging
Threat Response Plan and the requirements of
paragraph (1); and
``(ii) submit the results of the
independent evaluation to the appropriate
congressional committees.
``(6) Funding prohibitions.--None of the amounts made
available under this subsection may be obligated for any of the
following:
``(A) To supplant current anti-drug community-based
coalitions.
``(B) To supplant pro bono public service time
donated by national and local broadcasting network for
other public services campaigns.
``(C) For partisan political purposes, or express
advocacy in support of or to defeat any clearly
identified candidate, clearly identified ballot
initiative, or clearly identified legislative or
regulatory proposal.
``(D) For any advocacy in support of any particular
company, industry association, or advocacy group or the
explicit policy positions held by such groups.
``(E) To direct any individuals to a specific type
of substance use disorder treatment, treatment
facility, medical provider, or form of medication
assisted treatment.
``(F) To fund any advertising that features any
elected officials, persons seeking elected office,
cabinet level officials, or other Federal officials
employed pursuant to section 213 of Schedule C of title
5, Code of Federal Regulations.
``(e) Authorization of Appropriations.--There is authorized to be
appropriated to the Office to carry out this section, $25 million for
each of fiscal years 2019 through 2023.
``Sec. 1010. National and international coordination
``(a) Dissemination of Research and Information to States.--The
Director shall ensure that drug control research and information is
effectively disseminated by National Drug Control Program Agencies to
State and local governments and nongovernmental entities involved in
demand reduction by--
``(1) encouraging formal consultation between any such
agency that conducts or sponsors research, and any such agency
that disseminates information in developing research and
information product development agendas;
``(2) encouraging such agencies (as appropriate) to develop
and implement dissemination plans that specifically target
State and local governments and nongovernmental entities
involved in demand reduction; and
``(3) supporting the substance abuse information
clearinghouse administered by the Assistant Secretary for
Mental Health and Substance Use and established in section
501(d)(16) of the Public Health Service Act by--
``(A) encouraging all National Drug Control Program
Agencies to provide all appropriate and relevant
information; and
``(B) supporting the dissemination of information
to all interested entities.
``(b) Standards.--
``(1) Development.--The Director shall coordinate the
development of evidence-based standards developed by National
Drug Control Program Agencies and other relevant agencies and
non-Federal entities to State, local, and Tribal governments
and nongovernmental entities related to drug control policies,
practices, and procedures, such as the investigation of drug-
related deaths, by--
``(A) encouraging appropriate agencies and State,
local, and Tribal governments to develop data standards
for drug control practices and procedures and related
statistical data;
``(B) encouraging information sharing between
appropriate agencies and State, local, and Tribal
governments of relevant drug control information and
data;
``(C) establishing a working group of agencies,
State, local, and Tribal governments, and other
relevant stakeholders to discuss and develop such
standards; and
``(D) facilitating collaboration among agencies,
non-Federal entities, States, local, and Tribal
governments, and nongovernmental agencies.
``(2) Implementation.--The Director shall promote the
implementation of the standards described in paragraph (1) by--
``(A) encouraging adoption by providing the
standards to State and local governments through the
internet, annual publications or periodicals, and other
widely-disseminated means; and
``(B) facilitating the use and dissemination of
such standards among State and local governments by--
``(i) providing technical assistance to
State, local, and Tribal governments seeking to
adopt or implement such standards; and
``(ii) coordinating seminars and training
sessions for State, local, and Tribal
governments seeking to adopt or implement such
standards.
``(c) Private Sector.--
``(1) In general.--The Director or the head of a National
Drug Control Program (as designated by the Director) shall
coordinate with the private sector to promote private research
and development of medications to treat or prevent addiction,
including research and development for non-addictive pain
management medication, abuse deterrent formulations,
medication-assisted treatment, and other addiction research
determined to be necessary by the Director by--
``(A) encouraging the sharing of information
regarding evidence-based treatment addiction findings
and related data between agencies and the private
sector, as appropriate;
``(B) encouraging collaboration between appropriate
agencies and the private sector; and
``(C) providing private sector entities with
relevant statistical data and information to enhance
research as permissible.
``(2) Working group.--The Director may establish a working
group of National Drug Control Program Agencies, State, local,
and Tribal governments, and the private sector stakeholders to
discuss and disseminate best practices, research and
development, and other related issues, as appropriate.
``(d) Model Acts Program.--
``(1) In general.--The Director shall provide for or shall
enter into an agreement with a nonprofit organization to--
``(A) advise States on establishing laws and
policies to address illicit drug use issues; and
``(B) revise such model State drug laws and draft
supplementary model State laws to take into
consideration changes in illicit drug use issues in the
State involved.
``(2) Authorization of appropriations.--There is authorized
to be appropriated to carry out this subsection $1.25 million
for each of fiscal years 2019 through 2023.
``(e) Drug Court Training and Technical Assistance Program.--
``(1) Grants authorized.--The Director may make a grant to
a nonprofit organization for the purpose of providing training
and technical assistance to drug courts.
``(2) Authorization of appropriations.--There is authorized
to be appropriated to carry out this subsection $2 million for
each of fiscal years 2019 through 2023.
``(f) International Coordination.--The Director may facilitate
international drug control coordination efforts.
``(g) State, Local, and Tribal Affairs Coordinator.--The Director
shall designate or appoint a United States State, Local, and Tribal
Affairs Coordinator to perform the duties of the Office outlined in
this section and section 1005 and such other duties as may be
determined by the Director with respect to coordination of drug control
efforts between agencies and State, local, and Tribal governments. The
Director shall determine whether the coordinator position is a
noncareer appointee in the Senior Executive Service or a career
appointee at the GS-15 level (or equivalent) or above.
``Sec. 1011. Interdiction
``(a) United States Interdiction Coordinator.--
``(1) In general.--The Director shall designate or appoint
a noncareer appointee in the Senior Executive Service or a
career appointee at the GS-15 level (or equivalent) or above as
the United States Interdiction Coordinator to perform the
duties of that position described in paragraph (2) and such
other duties as may be determined by the Director with respect
to coordination of efforts to interdict illicit drugs from
entering the United States.
``(2) Responsibilities.--The United States Interdiction
Coordinator shall be responsible to the Director for--
``(A) coordinating the interdiction activities of
the National Drug Control Program Agencies to ensure
consistency with the National Drug Control Strategy;
``(B) on behalf of the Director, developing and
issuing, on or before September 1 of each year and in
accordance with paragraph (4), a National Interdiction
Command and Control Plan to ensure the coordination and
consistency described in subparagraph (A);
``(C) assessing the sufficiency of assets committed
to illicit drug interdiction by the relevant National
Drug Control Program Agencies; and
``(D) advising the Director on the efforts of each
National Drug Control Program Agency to implement the
National Interdiction Command and Control Plan.
``(3) Staff.--The Director shall assign such permanent
staff of the Office as he considers appropriate to assist the
United States Interdiction Coordinator to carry out the
responsibilities described in paragraph (2), and may request
that appropriate National Drug Control Program Agencies detail
or assign staff to assist in carrying out such activities.
``(4) National interdiction command and control plan.--
``(A) Purposes.--The National Interdiction Command
and Control Plan--
``(i) shall set forth the Government's
strategy for drug interdiction;
``(ii) shall state the specific roles and
responsibilities of the relevant National Drug
Control Program Agencies for implementing that
strategy; and
``(iii) shall identify the specific
resources required to enable the relevant
National Drug Control Program Agencies to
implement that strategy.
``(B) Consultation with other agencies.--Before the
submission of the National Drug Control Strategy or
annual supplement required under section 1005(d), as
applicable, the United States Interdiction Coordinator
shall issue the National Interdiction Command and
Control Plan, in consultation with the other members of
the Interdiction Committee described in subsection (b).
``(C) Report to congress.--On or before September 1
of each year, the Director, through the United States
Interdiction Coordinator, shall provide to the
appropriate congressional committees, to the Committee
on Armed Services and the Committee on Homeland
Security of the House of Representatives, and to the
Committee on Homeland Security and Governmental Affairs
and the Committee on Armed Services of the Senate, a
report that--
``(i) includes--
``(I) a copy of that year's
National Interdiction Command and
Control Plan;
``(II) information for the previous
10 years regarding the number and type
of seizures of drugs by each National
Drug Control Program Agency conducting
drug interdiction activities and
statistical information on the
geographic areas of such seizures; and
``(III) information for the
previous 10 years regarding the number
of air and maritime patrol hours
undertaken by each National Drug
Control Program Agency conducting drug
interdiction activities and statistical
information on the geographic areas in
which such patrol hours took place; and
``(ii) may include recommendations about
changes to existing agency authorities or laws
governing interagency relationships.
``(D) Classified annex.--The report submitted
pursuant to subparagraph (C) may include a classified
annex.
``(b) Interdiction Committee.--
``(1) In general.--The Interdiction Committee shall meet
to--
``(A) discuss and resolve issues related to the
coordination, oversight, and integration of
international, border, and domestic drug interdiction
efforts in support of the National Drug Control
Strategy;
``(B) review the annual National Interdiction
Command and Control Plan, and provide advice to the
Director and the United States Interdiction Coordinator
concerning that plan; and
``(C) provide such other advice to the Director
concerning drug interdiction strategy and policies as
the committee determines is appropriate.
``(2) Chair.--The Director shall designate one of the
members of the Interdiction Committee to serve as Chair.
``(3) Meetings.--The members of the Interdiction Committee
shall meet, in person and not through any delegate or
representative, at least once per calendar year, before June 1.
At the call of the Director or the Chair, the Interdiction
Committee may hold additional meetings, which shall be attended
by the members in person, or through such delegates or
representatives as the members may choose.
``(4) Report.--Not later than September 30 of each year,
the Chair of the Interdiction Committee shall submit to the
Director and to the appropriate congressional committees a
report describing the results of the meetings and any
significant findings of the committee during the previous 12
months. Such report may include a classified annex.
``Sec. 1012. Treatment coordinator
``(a) United States Treatment Coordinator.--
``(1) In general.--The Director shall designate or appoint
a noncareer appointee in the Senior Executive Service or a
career appointee at the GS-15 level (or equivalent) or above as
the United States Treatment Coordinator to perform the
responsibilities of that position described in paragraph (2)
and such other duties as may be determined by the Director with
respect to coordination of efforts to expand the availability
of substance use disorder treatment with the goal of
eliminating the unmet treatment need.
``(2) Responsibilities.--The United States Treatment
Coordinator shall be responsible to the Director for--
``(A) coordinating the activities of the National
Drug Control Program Agencies undertaken to expand the
availability of evidence-based substance use disorder
treatment to ensure consistency with the National Drug
Control Strategy;
``(B) on behalf of the Director, developing and
issuing, on or before September 1 of each year and in
accordance with paragraph (4), a National Treatment
Plan to ensure the coordination and consistency
described in subparagraph (A);
``(C) assessing the sufficiency of Federal
resources directed to substance use disorder treatment
by the relevant National Drug Control Program Agencies;
``(D) encouraging the adoption by all substance use
disorder treatment providers of evidence-based
standards to guide all aspects of treatment provided;
and
``(E) advising the Director on the efforts of each
National Drug Control Program Agency to implement the
National Treatment Plan.
``(3) Staff.--The Director shall assign such permanent
staff of the Office of the United States Treatment Coordinator
as the Director determines to be appropriate to assist the
United States Treatment Coordinator to carry out the
responsibilities described in paragraph (2), and may request
that appropriate National Drug Control Program Agencies detail
or assign staff to assist in carrying out such
responsibilities.
``(4) National treatment plan.--
``(A) Purposes.--The National Treatment Plan--
``(i) shall identify the unmet need for
treatment for evidence-based substance use
disorders and set forth the Government's
strategy for closing the gap between available
and needed treatment through all sources;
``(ii) shall describe the specific roles
and responsibilities of the relevant National
Drug Control Program Agencies for implementing
that strategy;
``(iii) shall identify the specific
resources required to enable the relevant
National Drug Control Program Agencies to
implement that strategy;
``(iv) shall identify the resources,
including private sources, required to
eliminate the unmet need for evidence-based
substance use disorder treatment; and
``(v) may include recommendations about
changes to existing agency authorities or laws
governing interagency relationships.
``(B) Consultation with other agencies.--Before the
submission of the National Treatment Strategy or annual
supplement required under section 1005(d), as
applicable, the United States Treatment Coordinator
shall issue the National Treatment Plan, in
consultation with the other members of the Treatment
Committee described in subsection (b).
``(C) Report to congress.--On or before September 1
of each year, the Director, through the United States
Treatment Coordinator, shall provide to the appropriate
congressional committees a report that includes a copy
of that year's National Treatment Plan.
``(b) Treatment Committee.--
``(1) In general.--The Treatment Committee shall meet to--
``(A) review and discuss the adequacy of evidence-
based substance use disorder treatment as well as the
unmet need for treatment;
``(B) review and discuss the status of the
implementation of the National Treatment Plan; and
``(C) provide such other advice to the Director
concerning substance use disorder treatment initiatives
as the committee determines is appropriate.
``(2) Chair.--The Director shall designate one of the
members of the Treatment Committee to serve as Chair.
``(3) Meetings.--The members of the Treatment Committee
shall meet, in person and not through any delegate or
representative, at least once per calendar year, before June 1.
At the call of the Director or the Chair, the Treatment
Committee may hold additional meetings, which shall be attended
by the members in person, or through such delegates or
representatives as the members may choose.
``(4) Report.--Not later than September 30 of each year,
the Chair of the Treatment Committee shall submit to the
Director and to the appropriate congressional committees a
report describing the results of the meetings and any
significant findings of the committee during the previous 12
months. Such report may include a classified annex.
``Sec. 1013. Critical information coordination
``(a) National Drug Control Fusion Center.--
``(1) Establishment.--The Director shall, in consultation
with the head of each National Drug Control Program Agency,
designate an agency to establish a National Drug Control Fusion
Center (referred to in this section as the `Center'). The
Center shall operate under the authority of the Director and
shall work with the National Drug Control Program Agencies to
collect, compile, analyze, and facilitate the sharing of data
on the use of illicit drugs, treatment for substance use
disorder, and interdiction of illicit drugs. The Center shall
be considered a `statistical agency or unit', as that term is
defined in section 502 of the Confidential Information
Protection and Statistical Efficiency Act of 2002 (44 U.S.C.
3501 note) and shall have the necessary independence to ensure
any data or information acquired by an agency under a pledge of
confidentiality and for exclusively statistical purposes is
used exclusively for statistical purposes.
``(2) Center director.--There shall be at the head of the
Center a Center Director who shall be appointed by the Director
from among individuals qualified and distinguished in data
governance and statistical analysis.
``(3) Data compilation.--The Director, acting through the
Center Director, shall do the following:
``(A) Coordinate data collection activities among
the National Drug Control Program Agencies.
``(B) Collect information not otherwise collected
by National Drug Control Program Agencies as necessary
to inform the National Drug Control Strategy.
``(C) Compile and analyze any data required to be
collected under this chapter.
``(D) Disseminate technology, as appropriate, to
States and local jurisdictions to enable or improve the
collection of data on drug use, including the
recordation of the occurrence of fatal and non-fatal
drug overdoses.
``(E) Compile information collected by National
Drug Control Program Agencies on grants issued through
any National Drug Control Program, including for any
grant the following:
``(i) The recipient.
``(ii) The amount.
``(iii) The intended purpose.
``(iv) Any evidence of the efficacy of the
outcomes achieved by the program funded through
the grant.
``(v) Any assessments of how the grant met
its intended purpose.
``(4) Toxicology screening.--
``(A) Establishment.--The Center Director may
establish a toxicology screening program that engages
in--
``(i) secondary analysis of urine samples
that would otherwise be discarded by--
``(I) hospitals and substance use
disorder treatment programs;
``(II) correctional facilities,
booking sites, probation programs, drug
courts, and related facilities; and
``(III) coroners and medical
examiners; and
``(ii) analysis of other physical samples,
as determined by the Center Director to be
valuable for understanding the prevalence of
any illicit drug.
``(B) De-identification of information.--The Center
Director shall ensure that no samples have any
personally identifiable information prior to
collection.
``(C) Limitation on use.--No data obtained from
analysis conducted under this paragraph may be used as
evidence in any proceeding.
``(D) State program.--The Center Director may
establish a program that enables States and local
jurisdictions to submit up to 20 urine samples per year
for toxicology analysis for the purposes of identifying
substances present in individuals who have suffered
fatal drug overdoses.
``(5) Authority to contract.--The Director may award
contracts, enter into interagency agreements, manage individual
projects, and conduct other operational activities under this
subsection.
``(b) Critical Drug Control Information and Evidence Plan.--
``(1) In general.--Not later than the first Monday in
February of each year, the Director shall submit to Congress a
systematic plan for increasing data collection to enable real-
time surveillance of drug control threats, developing analysis
and monitoring capabilities, and identifying and addressing
policy questions relevant to the National Drug Control Policy,
Strategy, and Program. Such plan shall be made available on the
public online portal of the Office, shall cover at least a 4-
year period beginning with the first fiscal year following the
fiscal year in which the plan is submitted and published, and
contain the following:
``(A) A list of policy-relevant questions for which
the Director and each National Drug Control Program
Agency intends to develop evidence to support the
National Drug Control Program and Strategy.
``(B) A list of data the Director and each National
Drug Control Program Agency intends to collect, use, or
acquire to facilitate the use of evidence in drug
control policymaking and monitoring.
``(C) A list of methods and analytical approaches
that may be used to develop evidence to support the
National Drug Control Program and Strategy and related
policy.
``(D) A list of any challenges to developing
evidence to support policymaking, including any
barriers to accessing, collecting, or using relevant
data.
``(E) A description of the steps the Director and
the head of each National Drug Control Program Agency
will take to effectuate the plan.
``(F) Any other relevant information as determined
by the Director.
``(2) Consultation.--In developing the plan required under
paragraph (1), the Director shall consult with the following:
``(A) The public.
``(B) Any evaluation or analysis units and
personnel of the Office.
``(C) Office officials responsible for implementing
privacy policy.
``(D) Office officials responsible for data
governance.
``(E) The appropriate congressional committees.
``(F) Any other individual or entity as determined
by the Director.
``(c) Evidence-Based Policy.--
``(1) Harm reduction programs.--When developing the
national drug control policy, any policy of the Director,
including policies relating to syringe exchange programs for
intravenous drug users, shall be based on the best available
medical and scientific evidence regarding the effectiveness of
such policy in promoting individual health, preventing the
spread of infectious disease and the impact of such policy on
drug addiction and use. In making any policy relating to harm
reduction programs, the Director shall consult with the
National Institutes of Health and the National Academy of
Sciences.
``(2) Fund restriction for the legalization of controlled
substances.--The Director shall ensure that no Federal funds
appropriated to the Office shall be expended for any study or
contract relating to the legalization (for a medical use or any
other use) for which a listing in schedule I is in effect under
section 202 of the Controlled Substances Act (21 U.S.C. 812).
``(d) Drug Control Data Dashboard.--
``(1) Establishment.--The Director, in consultation with
the Center Director, shall establish and maintain a data
dashboard on the online portal of the Office to be known as the
`Drug Control Data Dashboard'. The Director shall ensure the
user interface of the dashboard is constructed with modern
design standards. To the extent practicable, the data made
available on the dashboard shall be publicly available in a
machine-readable format and searchable by year, agency, drug,
and location.
``(2) Data.--The data included in the Drug Control Data
Dashboard shall be updated quarterly to the extent practicable,
but not less frequently than annually and shall include, at a
minimum, the following:
``(A) For each substance identified under section
1005(c)(1)(A)(i)--
``(i) the total amount seized and disrupted
in the calendar year and each of the previous 3
calendar years, including to the extent
practicable the amount seized by State, local,
and Tribal governments;
``(ii) the known and estimated flows into
the United States from all sources in the
calendar year and each of the previous 3
calendar years;
``(iii) the total amount of known flows
that could not be interdicted or disrupted in
the calendar year and each of the previous 3
calendar years;
``(iv) the known and estimated levels of
domestic production in the calendar year and
each of the previous 3 calendar years,
including the levels of domestic production if
the drug is a prescription drug, as determined
under the Federal Food, Drug, and Cosmetic Act,
for which a listing is in effect under section
202 of the Controlled Substances Act (21 U.S.C.
812);
``(v) the average street price for the
calendar year and the highest known street
price during the preceding 10-year period; and
``(vi) to the extent practicable, related
prosecutions by State, local, and Tribal
governments.
``(B) For the calendar year and each of the
previous 3 years data sufficient to show, disaggregated
by State and, to the extent feasible, by region within
a State, county, or city, the following:
``(i) The number of fatal and non-fatal
overdoses caused by each drug identified under
subparagraph (A)(i).
``(ii) The prevalence of substance use
disorders.
``(iii) The number of individuals who have
received substance use disorder treatment,
including medication assisted treatment, for a
substance use disorder, including treatment
provided through publicly-financed health care
programs.
``(iv) The extent of the unmet need for
substance use disorder treatment, including the
unmet need for medication-assisted treatment.
``(C) Data sufficient to show the extent of
prescription drug diversion, trafficking, and misuse in
the calendar year and each of the previous 3 calendar
years.
``(D) Any quantifiable measures the Director
determines to be appropriate to detail progress toward
the achievement of the goals of the National Drug
Control Strategy.
``(e) Access to Information.--
``(1) In general.--Upon the request of the Director, the
head of any National Drug Control Program Agency shall
cooperate with and provide to the Director any statistics,
studies, reports, and other information prepared or collected
by the agency concerning the responsibilities of the agency
under the National Drug Control Strategy that relate to--
``(A) drug control; or
``(B) the manner in which amounts made available to
that agency for drug control are being used by that
agency.
``(2) Protection of intelligence information.--
``(A) In general.--The authorities conferred on the
Office and the Director by this chapter shall be
exercised in a manner consistent with provisions of the
National Security Act of 1947 (50 U.S.C. 401 et seq.).
The Director of National Intelligence shall prescribe
such regulations as may be necessary to protect
information provided pursuant to this chapter regarding
intelligence sources and methods.
``(B) Duties of director.--The Director of National
Intelligence and the Director of the Central
Intelligence Agency shall, to the maximum extent
practicable in accordance with subparagraph (A), render
full assistance and support to the Office and the
Director.
``(3) Required reports from national drug control program
agencies.--The head of each National Drug Control Program
Agency shall submit to the Director such information and
reports as requested from such National Drug Control Program
Agency by the Director, which shall include from the
appropriate National Drug Control Program Agencies:
``(A) Not later than July 1 of each year, the head
of a National Drug Control Program Agency designated by
the Director shall submit to the Director and the
appropriate congressional committees an assessment of
the quantity of illegal drug cultivation and
manufacturing in the United States on lands owned or
under the jurisdiction of their respective agencies
that was seized or eradicated by their personnel during
the preceding calendar year.
``(B) Not later than July 1 of each year, the head
of a designated National Drug Control Program Agency
shall submit to the Director and the appropriate
congressional committees information for the preceding
year regarding--
``(i) the number and type of seizures of
drugs by each component of the agency seizing
drugs, as well as statistical information on
the geographic areas of such seizures; and
``(ii) the number of air and maritime
patrol hours primarily dedicated to drug supply
reduction missions undertaken by each component
of the agency.
``(C) Not later than July 1 of each year, the head
of a designated National Drug Control Program Agency
shall submit to the Director and the appropriate
congressional committees information for the preceding
year regarding the number of air and maritime patrol
hours primarily dedicated to drug supply reduction
missions undertaken by each component of the agency.
``(D) Not later than July 1 of each year, the head
of a designated National Drug Control Program Agency
shall submit to the Director and the appropriate
congressional committees information for the preceding
year regarding the number and type of--
``(i) arrests for drug violations;
``(ii) prosecutions by United States
Attorneys for drug violations; and
``(iii) seizures of drugs by each component
of the Department of Justice seizing drugs, as
well as statistical information on the
geographic areas of such seizures.
``(f) Data Exchange Standards for Improved Interoperability.--
``(1) Interagency and intergovernmental designation and use
of data exchange standards working group.--The Director shall
establish a working group of National Drug Control Program
Agencies, State, local and Tribal government health and law
enforcement agencies, and data governance experts to develop
consensus data exchange standards for necessary categories of
information that allow effective electronic exchange of
information between States, between State agencies, between
States and National Drug Control Program Agencies, and any
other drug control relevant data exchange.
``(2) Data exchange standards must be nonproprietary and
interoperable.--The data exchange standards developed under
paragraph (1) shall, to the extent practicable, be
nonproprietary and interoperable.
``(3) Other requirements.--In developing data exchange
standards under this subsection, the working group shall, to
the extent practicable, incorporate--
``(A) interoperable standards developed and
maintained by an international voluntary consensus
standards body, as defined by the Office of Management
and Budget;
``(B) interoperable standards developed and
maintained by intergovernmental partnerships; and
``(C) interoperable standards developed and
maintained by Federal entities with authority over
contracting and financial assistance.
``(4) Data exchange standards for federal reporting.--
``(A) Designation.--The Director may, in
consultation with the working group established under
this subsection, National Drug Control Program
Agencies, and State, local, and Tribal governments,
designate data exchange standards to govern Federal
reporting and exchange requirements for National Drug
Control Programs, as appropriate.
``(B) Requirements.--The data exchange reporting
standards designated under subparagraph (A) shall, to
the extent practicable--
``(i) incorporate a widely accepted,
nonproprietary, searchable, machine-readable
format;
``(ii) be consistent with and implement
applicable accounting principles;
``(iii) be implemented in a manner that is
cost-effective and improves program efficiency
and effectiveness; and
``(iv) be capable of being continually
upgraded as necessary.
``(C) Incorporation of nonproprietary standards.--
In designating data exchange standards under this
paragraph, the Director shall, to the extent
practicable, incorporate existing nonproprietary
standards.
``(D) Rule of construction.--Nothing in this
paragraph shall be construed to require a change to
existing data exchange standards for Federal reporting
about a program referred to in this section, if the
head of the agency responsible for administering the
program finds the standards to be effective and
efficient.
``(5) Termination.--The working group established under
paragraph (1) shall terminate not earlier than 60 days after
the public notification of termination by the Director.
``(g) Annual Data Collection and Dissemination Requirements.--
``(1) In general.--The Director shall collect and
disseminate, as appropriate, such information as the Director
determines is appropriate, but not less than the information
described in this subsection. To the extent practicable, the
data shall be publicly available in a machine-readable format
on the Drug Control Data Dashboard, be searchable by year,
agency, drug, and location, and cover not less than the
previous 10-year period.
``(2) Preparation and dissemination of information.--The
Director shall prepare and disseminate the following:
``(A) An assessment of current illicit drug use
(including inhalants and steroids) and availability,
impact of illicit drug use, and treatment availability,
which assessment shall include--
``(i) estimates of drug prevalence and
frequency of use as measured by national,
State, and local surveys of illicit drug use
and by other special studies of nondependent
and dependent illicit drug use;
``(ii) illicit drug use in the workplace
and the productivity lost by such use; and
``(iii) illicit drug use by arrestees,
probationers, and parolees.
``(B) An assessment of the reduction of illicit
drug availability, for each drug identified under
section 1005(c)(1)(A)(i), as measured by--
``(i) the quantities of such drug available
for consumption in the United States;
``(ii) the amount of such drug entering the
United States;
``(iii) the number of illicit drug
manufacturing laboratories seized and destroyed
of each such drug and the number of hectares
cultivated and destroyed domestically and in
other countries of such drug;
``(iv) the number of metric tons of such
drug seized; and
``(v) changes in the price and purity of
such drug.
``(C) An assessment of the reduction of the
consequences of illicit drug use and availability,
which shall include--
``(i) the cost of treating substance use
disorder in the United States, such as the
quantity of illicit drug-related services
provided;
``(ii) the annual national health care cost
of illicit drug use; and
``(iii) the extent of illicit drug-related
crime and criminal activity.
``(D) A determination of the status of substance
use disorder treatment in the United States, by
assessing--
``(i) public and private treatment
utilization; and
``(ii) the number of illicit drug users the
Director estimates meet diagnostic criteria for
treatment.
``Sec. 1014. Authorization of appropriations
``There are authorized to be appropriated to carry out this
chapter, except as otherwise specified, to remain available until
expended, $18.4 million for each of fiscal years 2019 through 2023.
``SUBCHAPTER II--DRUG-FREE COMMUNITIES SUPPORT PROGRAM
``Sec. 1021. Establishment of drug-free communities support program
``(a) Establishment.--The Director shall establish a program to
support communities in the development and implementation of
comprehensive, long-term plans and programs to prevent and treat
substance use and misuse among youth.
``(b) Program.--In carrying out the Program, the Director shall--
``(1) make and track grants to grant recipients;
``(2) provide for technical assistance and training, data
collection, and dissemination of information on state-of-the-
art practices that the Director determines to be effective in
reducing substance use; and
``(3) provide for the general administration of the
Program.
``(c) Administration.--The Director shall appoint an Administrator
to carry out the Program.
``(d) Contracting.--The Director may employ any necessary staff and
may enter into contracts or agreements with National Drug Control
Program Agencies, including interagency agreements, to delegate
authority for the execution of grants and for such other activities
necessary to carry out this chapter.
``Sec. 1022. Program authorization
``(a) Grant Eligibility.--To be eligible to receive an initial
grant or a renewal grant under this subchapter, a coalition shall meet
each of the following criteria:
``(1) Application.--The coalition shall submit an
application to the Administrator in accordance with section
1023(a)(2).
``(2) Major sector involvement.--
``(A) In general.--The coalition shall consist of
one or more representatives of each of the following
categories:
``(i) Youth.
``(ii) Parents.
``(iii) Businesses.
``(iv) The media.
``(v) Schools.
``(vi) Organizations serving youth.
``(vii) Law enforcement.
``(viii) Religious or fraternal
organizations.
``(ix) Civic and volunteer groups.
``(x) Health care professionals.
``(xi) State, local, or Tribal governmental
agencies with expertise in the field of
substance use prevention or substance use
disorders (including, if applicable, the State
authority with primary authority for substance
use and misuse).
``(xii) Other organizations involved in
reducing the prevalence of substance use and
misuse or substance use disorders.
``(B) Elected officials.--If feasible, in addition
to representatives from the categories listed in
subparagraph (A), the coalition shall have an elected
official (or a representative of an elected official)
from--
``(i) the Federal Government; and
``(ii) the government of the appropriate
State and political subdivision thereof or the
governing body or an Indian tribe (as that term
is defined in section 4(e) of the Indian Self-
Determination Act (25 U.S.C. 5304)).
``(C) Representation.--An individual who is a
member of the coalition may serve on the coalition as a
representative of not more than one category listed
under subparagraph (A).
``(3) Commitment.--The coalition shall demonstrate, to the
satisfaction of the Administrator--
``(A) that the representatives of the coalition
have worked together on substance use and misuse
reduction initiatives, which, at a minimum, includes
initiatives that target drugs described in section
1027(6)(A), for a period of not less than 6 months,
acting through entities such as task forces,
subcommittees, or community boards; and
``(B) substantial participation from volunteer
leaders in the community involved (especially in
cooperation with individuals involved with youth such
as parents, teachers, coaches, youth workers, and
members of the clergy).
``(4) Mission and strategies.--The coalition shall, with
respect to the community involved--
``(A) have as its principal mission the reduction
of illegal drug use, which, at a minimum, includes the
use of illegal drugs described in section 1027(6)(A),
in a comprehensive and long-term manner, with a primary
focus on youth in the community;
``(B) describe and document the nature and extent
of the substance use and misuse problem, which, at a
minimum, includes the use and misuse of drugs described
in section 1027(6)(A), in the community;
``(C)(i) provide a description of substance use and
misuse prevention and treatment programs and
activities, which, at a minimum, includes programs and
activities relating to the use and misuse of drugs
described in section 1027(6)(A), in existence at the
time of the grant application; and
``(ii) identify substance use and misuse programs
and service gaps, which, at a minimum, includes
programs and gaps relating to the use and misuse of
drugs described in section 1027(6)(A), in the
community;
``(D) develop a strategic plan to reduce substance
use and misuse among youth, which, at a minimum,
includes the use and misuse of drugs described in
section 1027(6)(A), in a comprehensive and long-term
fashion; and
``(E) work to develop a consensus regarding the
priorities of the community to combat substance use and
misuse among youth, which, at a minimum, includes the
use and misuse of drugs described in section
1027(6)(A).
``(5) Sustainability.--The coalition shall demonstrate that
the coalition is an ongoing concern by demonstrating that the
coalition--
``(A) is--
``(i)(I) a nonprofit organization; or
``(II) an entity that the Administrator
determines to be appropriate; or
``(ii) part of, or is associated with, an
established legal entity;
``(B) receives financial support (including, in the
discretion of the Administrator, in-kind contributions)
from non-Federal sources; and
``(C) has a strategy to solicit substantial
financial support from non-Federal sources to ensure
that the coalition and the programs operated by the
coalition are self-sustaining.
``(6) Accountability.--The coalition shall--
``(A) establish a system to measure and report
outcomes--
``(i) consistent with common indicators and
evaluation protocols established by the
Administrator; and
``(ii) approved by the Administrator;
``(B) conduct--
``(i) for an initial grant under this
subchapter, an initial benchmark survey of drug
use among youth (or use local surveys or
performance measures available or accessible in
the community at the time of the grant
application); and
``(ii) biennial surveys (or incorporate
local surveys in existence at the time of the
evaluation) to measure the progress and
effectiveness of the coalition; and
``(C) provide assurances that the entity conducting
an evaluation under this paragraph, or from which the
coalition receives information, has experience--
``(i) in gathering data related to
substance use and misuse among youth; or
``(ii) in evaluating the effectiveness of
community anti-drug coalitions.
``(7) Additional criteria.--The Director shall not impose
any eligibility criteria on new applicants or renewal grantees
not provided in this chapter.
``(b) Grant Amounts.--
``(1) In general.--
``(A) Grants.--
``(i) In general.--Subject to clause (iv),
for a fiscal year, the Administrator may grant
to an eligible coalition under this paragraph,
an amount not to exceed the amount of non-
Federal funds raised by the coalition,
including in-kind contributions, for that
fiscal year.
``(ii) Suspension of grants.--If such grant
recipient fails to continue to meet the
criteria specified in subsection (a), the
Administrator may suspend the grant, after
providing written notice to the grant recipient
and an opportunity to appeal.
``(iii) Renewal grants.--Subject to clause
(iv), the Administrator may award a renewal
grant to a grant recipient under this
subparagraph for each fiscal year following the
fiscal year for which an initial grant is
awarded, in an amount not to exceed the amount
of non-Federal funds raised by the coalition,
including in-kind contributions, for that
fiscal year, during the 4-year period following
the period of the initial grant.
``(iv) Limitation.--The amount of a grant
award under this subparagraph may not exceed
$125,000 for a fiscal year.
``(B) Coalition awards.--
``(i) In general.--Except as provided in
clause (ii), the Administrator may, with
respect to a community, make a grant to one
eligible coalition that represents that
community.
``(ii) Exception.--The Administrator may
make a grant to more than one eligible
coalition that represents a community if--
``(I) the eligible coalitions
demonstrate that the coalitions are
collaborating with one another; and
``(II) each of the coalitions has
independently met the requirements set
forth in subsection (a).
``(2) Rural coalition grants.--
``(A) In general.--
``(i) In general.--In addition to awarding
grants under paragraph (1), to stimulate the
development of coalitions in sparsely populated
and rural areas, the Administrator may award a
grant in accordance with this section to a
coalition that represents a county with a
population that does not exceed 30,000
individuals. In awarding a grant under this
paragraph, the Administrator may waive any
requirement under subsection (a) if the
Administrator considers that waiver to be
appropriate.
``(ii) Matching requirement.--Subject to
subparagraph (C), for a fiscal year, the
Administrator may grant to an eligible
coalition under this paragraph, an amount not
to exceed the amount of non-Federal funds
raised by the coalition, including in-kind
contributions, for that fiscal year.
``(iii) Suspension of grants.--If such
grant recipient fails to continue to meet any
criteria specified in subsection (a) that has
not been waived by the Administrator pursuant
to clause (i), the Administrator may suspend
the grant, after providing written notice to
the grant recipient and an opportunity to
appeal.
``(B) Renewal grants.--The Administrator may award
a renewal grant to an eligible coalition that is a
grant recipient under this paragraph for each fiscal
year following the fiscal year for which an initial
grant is awarded, in an amount not to exceed the amount
of non-Federal funds raised by the coalition, including
in-kind contributions, during the 4-year period
following the period of the initial grant.
``(C) Limitations.--
``(i) Amount.--The amount of a grant award
under this paragraph shall not exceed $125,000
for a fiscal year.
``(ii) Awards.--With respect to a county
referred to in subparagraph (A), the
Administrator may award a grant under this
section to not more than one eligible coalition
that represents the county.
``(3) Additional grants.--
``(A) In general.--Subject to subparagraph (F), the
Administrator may award an additional grant under this
paragraph to an eligible coalition awarded a grant
under paragraph (1) or (2) for any first fiscal year
after the end of the 4-year period following the period
of the initial grant under paragraph (1) or (2), as the
case may be.
``(B) Scope of grants.--A coalition awarded a grant
under paragraph (1) or (2), including a renewal grant
under such paragraph, may not be awarded another grant
under such paragraph, and is eligible for an additional
grant under this section only under this paragraph.
``(C) No priority for applications.--The
Administrator may not afford a higher priority in the
award of an additional grant under this paragraph than
the Administrator would afford the applicant for the
grant if the applicant were submitting an application
for an initial grant under paragraph (1) or (2) rather
than an application for a grant under this paragraph.
``(D) Renewal grants.--Subject to subparagraph (F),
the Administrator may award a renewal grant to a grant
recipient under this paragraph for each of the fiscal
years of the 4-fiscal-year period following the fiscal
year for which the initial additional grant under
subparagraph (A) is awarded in an amount not to exceed
amounts as follows:
``(i) For the first and second fiscal years
of that 4-fiscal-year period, the amount of the
non-Federal funds, including in-kind
contributions, raised by the coalition for the
applicable fiscal year is not less than 125
percent of the amount awarded.
``(ii) For the third and fourth fiscal
years of that 4-fiscal-year period, the amount
of the non-Federal funds, including in-kind
contributions, raised by the coalition for the
applicable fiscal year is not less than 150
percent of the amount awarded.
``(E) Suspension.--If a grant recipient under this
paragraph fails to continue to meet the criteria
specified in subsection (a), the Administrator may
suspend the grant, after providing written notice to
the grant recipient and an opportunity to appeal.
``(F) Limitation.--The amount of a grant award
under this paragraph may not exceed $125,000 for a
fiscal year.
``(4) Process for suspension.--A grantee shall not be
suspended or terminated under paragraph (1)(A)(ii),
(2)(A)(iii), or (3)(E) unless that grantee is afforded a fair,
timely, and independent appeal prior to such suspension or
termination.
``(c) Treatment of Funds for Coalitions Representing Certain
Organizations.--Funds appropriated for the substance use and misuse
activities of a coalition that includes a representative of the Bureau
of Indian Affairs, the Indian Health Service, or a Tribal government
agency with expertise in the field of substance use prevention may be
counted as non-Federal funds raised by the coalition for purposes of
this section.
``(d) Priority in Awarding Grants.--In awarding grants under
subsection (b)(1)(A)(i), priority shall be given to a coalition serving
economically disadvantaged areas.
``Sec. 1023. Information collection and dissemination with respect to
grant recipients
``(a) Coalition Information.--
``(1) General auditing authority.--For the purpose of audit
and examination, the Administrator--
``(A) shall have access to any books, documents,
papers, and records that are pertinent to any grant or
grant renewal request under this subchapter; and
``(B) may periodically request information from a
grant recipient to ensure that the grant recipient
meets the applicable criteria under section 1022(a).
``(2) Application process.--The Administrator shall issue a
request for proposal regarding, with respect to the grants
awarded under section 1022, the application process, grant
renewal, and suspension or withholding of renewal grants. Each
application under this paragraph shall be in writing and shall
be subject to review by the Administrator.
``(3) Reporting.--The Administrator shall, to the maximum
extent practicable and in a manner consistent with applicable
law, minimize reporting requirements by a grant recipient and
expedite any application for a renewal grant made under this
subchapter.
``(b) Data Collection and Dissemination.--
``(1) In general.--The Administrator may collect data
from--
``(A) national substance use and misuse
organizations that work with eligible coalitions,
community anti-drug coalitions, departments or agencies
of the Federal Government, or State or local
governments and the governing bodies of Indian Tribes;
and
``(B) any other entity or organization that carries
out activities that relate to the purposes of the
Program.
``(2) Activities of administrator.--The Administrator may--
``(A) evaluate the utility of specific initiatives
relating to the purposes of the Program;
``(B) conduct an evaluation of the Program; and
``(C) disseminate information described in this
subsection to--
``(i) eligible coalitions and other
substance use prevention organizations; and
``(ii) the general public.
``(3) Consultation.--The Administrator shall carry out
activities under this subsection in consultation with the
National Community Antidrug Coalition Institute.
``(4) Limitation on use of certain funds for evaluation of
program.--Amounts for activities under paragraph (2)(B) may not
be derived from amounts under section 1028(a) except for
amounts that are available under section 1028(b) for
administrative costs.
``Sec. 1024. Technical assistance and training
``(a) In General.--
``(1) Technical assistance and agreements.--With respect to
any grant recipient or other organization, the Administrator
may--
``(A) offer technical assistance and training; and
``(B) enter into contracts and cooperative
agreements.
``(2) Coordination of programs.--The Administrator may
facilitate the coordination of programs between a grant
recipient and other organizations and entities.
``(b) Training.--The Administrator may provide training to any
representative designated by a grant recipient in--
``(1) coalition building;
``(2) task force development;
``(3) mediation and facilitation, direct service,
assessment and evaluation; or
``(4) any other activity related to the purposes of the
Program.
``Sec. 1025. Supplemental grants for coalition mentoring activities
``(a) Authority to Make Grants.--As part of the Program, the
Director may award an initial grant under this subsection, and renewal
grants under subsection (f), to any coalition awarded a grant under
section 1022 that meets the criteria specified in subsection (d) in
order to fund coalition mentoring activities by such coalition in
support of the program.
``(b) Treatment With Other Grants.--
``(1) Supplement.--A grant awarded to a coalition under
this section is in addition to any grant awarded to the
coalition under section 1022.
``(2) Requirement for basic grant.--A coalition may not be
awarded a grant under this section for a fiscal year unless the
coalition was awarded a grant or renewal grant under section
1022(b) for that fiscal year.
``(c) Application.--A coalition seeking a grant under this section
shall submit to the Administrator an application for the grant in such
form and manner as the Administrator may require.
``(d) Criteria.--A coalition meets the criteria specified in this
subsection if the coalition--
``(1) has been in existence for at least 5 years;
``(2) has achieved, by or through its own efforts,
measurable results in the prevention and treatment of substance
use and misuse among youth;
``(3) has staff or members willing to serve as mentors for
persons seeking to start or expand the activities of other
coalitions in the prevention and treatment of substance use and
misuse;
``(4) has demonstrable support from some members of the
community in which the coalition mentoring activities to be
supported by the grant under this section are to be carried
out; and
``(5) submits to the Administrator a detailed plan for the
coalition mentoring activities to be supported by the grant
under this section.
``(e) Use of Grant Funds.--A coalition awarded a grant under this
section shall use the grant amount for mentoring activities to support
and encourage the development of new, self-supporting community
coalitions that are focused on the prevention and treatment of
substance use and misuse in such new coalitions' communities. The
mentoring coalition shall encourage such development in accordance with
the plan submitted by the mentoring coalition under subsection (d)(5).
``(f) Renewal Grants.--The Administrator may make a renewal grant
to any coalition awarded a grant under subsection (a), or a previous
renewal grant under this subsection, if the coalition, at the time of
application for such renewal grant--
``(1) continues to meet the criteria specified in
subsection (d); and
``(2) has made demonstrable progress in the development of
one or more new, self-supporting community coalitions that are
focused on the prevention and treatment of substance use and
misuse.
``(g) Grant Amounts.--
``(1) In general.--Subject to paragraphs (2) and (3), the
total amount of grants awarded to a coalition under this
section for a fiscal year may not exceed the amount of non-
Federal funds raised by the coalition, including in-kind
contributions, for that fiscal year. Funds appropriated for the
substance use and misuse activities of a coalition that
includes a representative of the Bureau of Indian Affairs, the
Indian Health Service, or a Tribal government agency with
expertise in the field of substance use prevention may be
counted as non-Federal funds raised by the coalition.
``(2) Initial grants.--The amount of the initial grant
awarded to a coalition under subsection (a) may not exceed
$75,000.
``(3) Renewal grants.--The total amount of renewal grants
awarded to a coalition under subsection (f) for any fiscal year
may not exceed $75,000.
``(h) Fiscal Year Limitation on Amount Available for Grants.--The
total amount available for grants under this section, including renewal
grants under subsection (f), in any fiscal year may not exceed the
amount equal to 5 percent of the amount authorized to be appropriated
by section 1028 for that fiscal year.
``(i) Priority in Awarding Initial Grants.--In awarding initial
grants under this section, priority shall be given to a coalition that
expressly proposes to provide mentorship to a coalition or aspiring
coalition serving economically disadvantaged areas.
``Sec. 1026. Authorization for National Community Antidrug Coalition
Institute
``(a) In General.--The Director shall, using amounts authorized to
be appropriated by subsection (d), make a competitive grant to provide
for the continuation of the National Community Anti-drug Coalition
Institute.
``(b) Eligible Organizations.--An organization eligible for the
grant under subsection (a) is any national nonprofit organization that
represents, provides technical assistance and training to, and has
special expertise and broad, national-level experience in community
antidrug coalitions under this subchapter.
``(c) Use of Grant Amount.--The organization that receives the
grant under subsection (a) shall continue a National Community Anti-
Drug Coalition Institute to--
``(1) provide education, training, and technical assistance
for coalition leaders and community teams, with emphasis on the
development of coalitions serving economically disadvantaged
areas;
``(2) develop and disseminate evaluation tools, mechanisms,
and measures to better assess and document coalition
performance measures and outcomes; and
``(3) bridge the gap between research and practice by
translating knowledge from research into practical information.
``(d) Authorization of Appropriations.--The Director shall, using
amounts authorized to be appropriated by section 1028, make a grant of
$2 million under subsection (a), for each of the fiscal years 2019
through 2023.
``Sec. 1027. Definitions
``In this subchapter:
``(1) Administrator.--The term `Administrator' means the
Administrator appointed by the Director under section 1021(c).
``(2) Community.--The term `community' shall have the
meaning provided that term by the Administrator.
``(3) Eligible coalition.--The term `eligible coalition'
means a coalition that meets the applicable criteria under
section 1022(a).
``(4) Grant recipient.--The term `grant recipient' means
the recipient of a grant award under section 1022.
``(5) Program.--The term `Program' means the program
established under section 1021(a).
``(6) Substance use and misuse.--The term `substance use
and misuse' means--
``(A) the illegal use or misuse of drugs, including
substances for which a listing is in effect under any
of schedules I through V under section 202 of the
Controlled Substances Act (21 U.S.C. 812);
``(B) the misuse of inhalants or over the counter
drugs; or
``(C) the use of alcohol, tobacco, or other related
product as such use is prohibited by State or local
law.
``(7) Youth.--The term `youth' shall have the meaning
provided that term by the Administrator.
``Sec. 1028. Drug-free communities reauthorization
``(a) Authorization of Appropriations.--There are authorized to be
appropriated to the Office to carry out this subchapter $99 million for
each of the fiscal years 2019 through 2023.
``(b) Administrative Costs.--Not more than 8 percent of the funds
appropriated for this subchapter may be used by the Office or, in the
discretion of the Director, an agency delegated to carry out the
program under section 1021(d) to pay for administrative costs
associated with carrying out the program.''.
(d) Technical and Conforming Amendment.--The table of chapters for
subtitle I of title 31, United States Code, is amended by adding at the
end the following new item:
``10. Office of National Drug Control....................... 1001''.
SEC. 3. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM.
(a) Establishment.--
(1) In general.--There is established in the Office a
program to be known as the High Intensity Drug Trafficking
Areas Program (in this section referred to as the ``Program'').
(2) Purpose.--The purpose of the Program is to reduce drug
trafficking and drug production in the United States by--
(A) facilitating cooperation among Federal, State,
local, and Tribal law enforcement agencies to share
information and implement coordinated enforcement
activities;
(B) enhancing law enforcement intelligence sharing
among Federal, State, local, and Tribal law enforcement
agencies;
(C) providing reliable law enforcement intelligence
to law enforcement agencies needed to design effective
enforcement strategies and operations; and
(D) supporting coordinated law enforcement
strategies which maximize use of available resources to
reduce the supply of illegal drugs in designated areas
and in the United States as a whole.
(b) Designation.--
(1) In general.--The Director, in consultation with the
Attorney General, the Secretary of the Treasury, the Secretary
of Homeland Security, the head of each National Drug Control
Program Agency, and the Governor of each applicable State, may
designate any specified area of the United States as a high
intensity drug trafficking area.
(2) Activities.--After making a designation under paragraph
(1) and in order to provide Federal assistance to the area so
designated, the Director may--
(A) obligate such sums as are appropriated for the
Program;
(B) direct the temporary reassignment of Federal
personnel to such area, subject to the approval of the
head of the agency that employs such personnel;
(C) take any other action authorized under this
section or chapter 10 of title 31, United States Code,
as added by section 2(c), to provide increased Federal
assistance to those areas; and
(D) coordinate activities under this section
(specifically administrative, recordkeeping, and funds
management activities) with State, local, and Tribal
officials.
(c) Petitions for Designation.--The Director shall establish and
maintain regulations under which a coalition of interested law
enforcement agencies from an area may petition for designation as a
high intensity drug trafficking area (in this section referred to as
the ``HIDTA''). Such regulations shall provide for a regular review by
the Director of the petition, including a recommendation regarding the
merit of the petition to the Director by a panel of qualified,
independent experts.
(d) Factors for Consideration.--In considering whether to designate
an area under this section as a high intensity drug trafficking area,
the Director shall consider, in addition to such other criteria as the
Director considers to be appropriate, the extent to which--
(1) the area is a significant center of illegal drug
production, manufacturing, importation, or distribution;
(2) State, local, and Tribal law enforcement agencies have
committed resources to respond to the drug trafficking problem
in the area, thereby indicating a determination to respond
aggressively to the problem;
(3) drug-related activities in the area are having a
significant harmful impact in the area, and in other areas of
the country; and
(4) a significant increase in allocation of Federal
resources is necessary to respond adequately to drug-related
activities in the area.
(e) Organization of High Intensity Drug Trafficking Areas.--
(1) Executive board and officers.--To be eligible for funds
appropriated under this section, each high intensity drug
trafficking area shall be governed by an Executive Board. The
Executive Board shall designate a chairman, vice chairman, and
any other officers to the Executive Board that it determines
are necessary.
(2) Responsibilities.--The Executive Board of a high
intensity drug trafficking area shall be responsible for--
(A) providing direction and oversight in
establishing and achieving the goals of the high
intensity drug trafficking area;
(B) managing the funds of the high intensity drug
trafficking area;
(C) reviewing and approving all funding proposals
consistent with the overall objective of the high
intensity drug trafficking area; and
(D) reviewing and approving all reports to the
Director on the activities of the high intensity drug
trafficking area.
(3) Board representation.--None of the funds appropriated
under this section may be expended for any high intensity drug
trafficking area, or for a partnership or region of a high
intensity drug trafficking area, if the Executive Board for
such area, region, or partnership, does not apportion an equal
number of votes between representatives of participating
agencies and representatives of participating State, local, and
Tribal agencies. Where it is impractical for an equal number of
representatives of agencies and State, local, and Tribal
agencies to attend a meeting of an Executive Board in person,
the Executive Board may use a system of proxy votes or weighted
votes to achieve the voting balance required by this paragraph.
(4) No agency relationship.--The eligibility requirements
of this section are intended to ensure the responsible use of
Federal funds. Nothing in this section is intended to create an
agency relationship between individual high intensity drug
trafficking areas and the Federal Government.
(f) Use of Funds.--The Director shall ensure that not more than 5
percent of Federal funds appropriated for the Program are expended for
substance use disorder treatment programs and not more than 5 percent
of the Federal funds appropriated for the Program are expended for drug
prevention programs.
(g) Counterterrorism Activities.--
(1) Assistance authorized.--The Director may authorize use
of resources available for the Program to assist Federal,
State, local, and Tribal law enforcement agencies in
investigations and activities related to terrorism and
prevention of terrorism, especially but not exclusively with
respect to such investigations and activities that are also
related to drug trafficking.
(2) Limitation.--The Director shall ensure--
(A) that assistance provided under paragraph (1)
remains incidental to the purpose of the Program to
reduce drug availability and carry out drug-related law
enforcement activities; and
(B) that significant resources of the Program are
not redirected to activities exclusively related to
terrorism, except on a temporary basis under
extraordinary circumstances, as determined by the
Director.
(h) Role of Drug Enforcement Administration.--The Director, in
consultation with the Attorney General, shall ensure that a
representative of the Drug Enforcement Administration is included in
the Intelligence Support Center for each high intensity drug
trafficking area.
(i) Emerging Threat Response Fund.--
(1) In general.--Subject to the availability of
appropriations, the Director may expend up to 10 percent of the
amounts appropriated under this section on a discretionary
basis, in accordance with the criteria established under
paragraph (2)--
(A) to respond to any emerging drug trafficking
threat in an existing high intensity drug trafficking
area;
(B) to establish a new high intensity drug
trafficking area; or
(C) to expand an existing high intensity drug
trafficking area.
(2) Consideration of impact.--In allocating funds under
this subsection, the Director shall consider--
(A) the impact of activities funded on reducing
overall drug traffic in the United States, or
minimizing the probability that an emerging drug
trafficking threat will spread to other areas of the
United States; and
(B) such other criteria as the Director considers
appropriate.
(j) Annual HIDTA Program Budget Submissions.--As part of the
documentation that supports the President's annual budget request for
the Office, the Director shall submit to Congress a budget
justification that includes--
(1) the amount proposed for each HIDTA, conditional upon a
review by the Office of the request submitted by such HIDTA and
the performance of such HIDTA, with supporting narrative
descriptions and rationale for each request;
(2) a detailed justification that explains--
(A) the reasons for the proposed funding level and
how such funding level was determined based on a
current assessment of the drug trafficking threat in
each high intensity drug trafficking area;
(B) how such funding will ensure that the goals and
objectives of each such area will be achieved; and
(C) how such funding supports the National Drug
Control Strategy; and
(3) the amount of HIDTA funds used to investigate and
prosecute organizations and individuals trafficking in each
major illicit drug, as identified by the Director, in the prior
calendar year, and a description of how those funds were used.
(k) HIDTA Annual Evaluation Report.--As part of each report
submitted pursuant to section 1006(a) of title 31, United States Code,
as added by section 2(c), the Director shall include, for each
designated high intensity drug trafficking area, a report that--
(1) describes--
(A) the specific purposes for the high intensity
drug trafficking area; and
(B) the specific long-term and short-term goals and
objectives for the high intensity drug trafficking
area;
(2) includes an evaluation of the performance of the high
intensity drug trafficking area in accomplishing the specific
long-term and short-term goals and objectives identified under
subparagraph (1)(B);
(3) assesses the number and operation of all federally
funded drug enforcement task forces within such high intensity
drug trafficking area;
(4) describes--
(A) each Federal, State, local, and Tribal drug
enforcement task force operating in such high intensity
drug trafficking area;
(B) how such task forces coordinate with each
other, with any high intensity drug trafficking area
task force, and with investigations receiving funds
from the Organized Crime and Drug Enforcement Task
Force;
(C) what steps, if any, each such task force takes
to share information regarding drug trafficking and
drug production with other federally funded drug
enforcement task forces in the high intensity drug
trafficking area;
(D) the role of the high intensity drug trafficking
area in coordinating the sharing of such information
among task forces;
(E) the nature and extent of cooperation by each
Federal, State, local, and Tribal participant in
ensuring that such information is shared among law
enforcement agencies and with the high intensity drug
trafficking area;
(F) the nature and extent to which information
sharing and enforcement activities are coordinated with
joint terrorism task forces in the high intensity drug
trafficking area; and
(G) any recommendations for measures needed to
ensure that task force resources are utilized
efficiently and effectively to reduce the availability
of illegal drugs in the high intensity drug trafficking
areas; and
(5) in consultation with the Director of National
Intelligence--
(A) evaluates existing and planned law enforcement
intelligence systems supported by such high intensity
drug trafficking area, or utilized by task forces
receiving any funding under the Program, including the
extent to which such systems ensure access and
availability of law enforcement intelligence to
Federal, State, local, and Tribal law enforcement
agencies within the high intensity drug trafficking
area and outside of such area;
(B) evaluates the extent to which Federal, State,
local, and Tribal law enforcement agencies
participating in each high intensity drug trafficking
area are sharing law enforcement intelligence
information to assess current drug trafficking threats
and design appropriate enforcement strategies; and
(C) identifies the measures needed to improve
effective sharing of information and law enforcement
intelligence regarding drug trafficking and drug
production among Federal, State, local, and Tribal law
enforcement participating in a high intensity drug
trafficking area, and between such agencies and similar
agencies outside the high intensity drug trafficking
area.
(l) Coordination of Law Enforcement Intelligence Sharing With
Organized Crime Drug Enforcement Task Force Program.--
(1) Drug enforcement intelligence sharing.--The Director,
in consultation with the Attorney General, shall ensure that
any drug enforcement intelligence obtained by the Intelligence
Support Center for each high intensity drug trafficking area is
shared, on a timely basis, with the drug intelligence fusion
center operated by the Organized Crime Drug Enforcement Task
Force of the Department of Justice.
(2) Certification.--Before the Director awards any funds to
a high intensity drug trafficking area, the Director shall
certify that the law enforcement entities participating in that
HIDTA are providing laboratory seizure data to the national
clandestine laboratory database at the El Paso Intelligence
Center.
(m) Authorization of Appropriations.--There is authorized to be
appropriated to the Office to carry out this section $280 million for
each fiscal years 2019 through 2023.
(n) Specific Purposes.--
(1) In general.--The Director shall ensure that, of the
amounts appropriated for a fiscal year for the Program, at
least 2.5 percent is used in high intensity drug trafficking
areas with severe neighborhood safety and illegal drug
distribution problems.
(2) Required uses.--The funds used under paragraph (1)
shall be used to ensure the safety of neighborhoods and the
protection of communities, including the prevention of the
intimidation of witnesses of illegal drug distribution and
related activities and the establishment of or support for
programs that provide protection or assistance to witnesses in
court proceedings.
(3) Best practice models.--The Director shall work with the
HIDTAs to develop and maintain best practice models to assist
State, local, and Tribal governments in addressing witness
safety, relocation, financial and housing assistance, or any
other services related to witness protection or assistance in
cases of illegal drug distribution and related activities. The
Director shall ensure dissemination of the best practice models
to each HIDTA.
SEC. 4. OPIOID CRISIS RESPONSE.
(a) Emerging Threat Designation.--The Director shall designate
opioids and opioid analogues as emerging drug threats, in accordance
with section 1009 of title 31, United States Code, as added by section
2(c).
(b) Opioid Response Plan.--
(1) Issuance.--Not later than 60 days after the date of the
enactment of this Act, the Director shall publish, make
publicly available, and notify the President and the
appropriate congressional committees of, the plan required
under section 1009 of title 31, United States Code, as added by
section 2(c), to be designated as the ``National Opioid Crisis
Response Plan''.
(2) Contents.--The Director shall ensure the plan
establishes measurable goals, including reducing fatal and non-
fatal overdoses, and includes the following:
(A) An initiative to ensure the United States mail
is effectively screened to prevent illicit drugs from
entering the United States, including--
(i) designating the United States Postal
Service as a National Drug Control Program
Agency;
(ii) directing the United States Postal
Service and any other related National Drug
Control Program Agency to take any appropriate
actions necessary to reduce the amount of
illicit drugs entering the country; and
(iii) developing an international
coordination plan, in consultation with the
National Drug Control Program Agencies and in
accordance with section 1010 of such title 31,
United States Code, as added by section 2(c),
to include efforts to address international
drug control initiatives and strengthen
bilateral and multilateral strategies to reduce
illicit drugs and precursor chemicals from
entering the United States through
international mail or across land borders or
ports of entry.
(B) Support for universal adoption of evidence-
based prescribing guidelines, including--
(i) establishing a task force to supplement
existing prescribing guidelines with evidence-
based standards and to facilitate, coordinate,
and, as appropriate, conduct research to inform
such guidelines;
(ii) encouraging the adoption of evidence-
based prescribing guidelines by each relevant
agency, State and local governments, and
private sector organizations;
(iii) issuing guidance to National Drug
Control Program Agencies to, as appropriate,
revise regulations to ensure professionals have
effective continuing education requirements;
and
(iv) disseminating and encouraging the
adoption of best practices and evidence-based
guidelines for effective prescribing practices.
(C) A program to monitor the prescription drug
market and illicit drug market for changes in trends
relevant to reducing the supply or demand of such
drugs.
(D) An initiative to facilitate and coordinate
Federal, State and local government initiatives,
studies, and pilot or demonstration programs designed
to evaluate the benefits of drug courts and related
programs that reduce substance use prevalence.
(E) A program, developed in coordination with the
private sector, to--
(i) facilitate the development of treatment
and abuse-deterrent products, in accordance
with section 1010(c) of title 31, United States
Code, as added by section 2(c); and
(ii) encourage the expansion of medication
disposal programs and technology.
(F) Initiatives to--
(i) encourage the National Drug Control
Program Agencies and the program established
under section 1010(d) of title 31, United
States Code, as added by section 2(c), to
prioritize the development of sentencing
standards or model codes for trafficking
opioids and opioid analogues; and
(ii) to advise States on establishing laws
and policies to address opioid issues based on
the recommendations developed and set forth by
the President's Commission on Combating Drug
Addiction and the Opioid Crisis.
(G) A program to identify successful college
recovery programs, including sober housing programs
that provide a shared living residence free of alcohol
or illicit drug use for individuals recovering from
drug or alcohol addiction and substance use disorders,
on college campuses and disseminate best practices to
Colleges and Universities to increase the number and
capacity of such programs.
(H) Convening working groups, consisting of the
appropriate National Drug Control Program Agencies,
State, local and Tribal governments, and other
appropriate stakeholders, established in accordance
with section 1010 of title 31, United States Code, as
added by section 2(c)--
(i) to support Prescription Drug Monitoring
Programs by--
(I) facilitating the sharing and
interoperability of program data among
States and Federal prescription drug
monitoring programs;
(II) assisting States in increasing
utilization of such programs;
(III) facilitating efforts to
incorporate available overdose and
naloxone deployment data into such
programs;
(IV) evaluating barriers to
integrating program data with
electronic health records; and
(V) offering recommendations to
address identified barriers; and
(ii) to develop standards, and encourage
the use of such standards, for the collection
of data necessary to understand and monitor the
opioid crisis, including--
(I) State medical examiner reports
on deaths caused by overdoses and
related statistical data; and
(II) first responder opioid
intoxication incidents.
(I) Research initiatives, to be initiated not later
than 30 days after the issuance of the plan, to
evaluate the uses and barriers to use of and the
effects of improving the following programs:
(i) Medication Assisted Treatment.
(ii) Data collection systems used to
confirm opioid use by individuals who have been
arrested or hospitalized.
(J) A requirement for an Advisory Committee on
Substance Use Disorder Treatment Standards, to be
established not later than 120 days after the issuance
of the plan, to promulgate model evidence-based
standards for substance use disorder treatment and
recovery facilities which--
(i) shall be chaired by the Director;
(ii) shall include as members of the
advisory committee representatives of the
relevant National Drug Control Program
Agencies;
(iii) may include as members of the
advisory committee government regulators, State
representatives, consumer representatives,
substance use disorder treatment providers,
recovery residence owners and operators, and
purchasers of substance use disorder
treatments; and
(iv) shall ensure such model standards are
promulgated no later than 2 years after the
date of the issuance of the plan.
(c) Recommendations.--Not later than 1 year after the date of the
enactment of this Act, the Director shall submit to the appropriate
congressional committees a report on the results of the initiatives
conducted under subsection (b)(2)(I) and may include recommendations
based on such results.
(d) Grant Report to Congress.--Not later than 1 year after the date
of the enactment of this Act, the Director shall submit to the
appropriate congressional committees an assessment on the feasibility
of block grants of Federal funding to States.
SEC. 5. EXCEPTIONS AND RULES OF CONSTRUCTION.
(a) Inapplicability to Certain Programs.--This Act, and the
amendments made by this Act, shall not apply to the National
Intelligence Program and the Military Intelligence Program, unless such
program or an element of such program is designated as a National Drug
Control Program--
(1) by the President; or
(2) jointly by--
(A) in the case of the National Intelligence
Program, the Director and the Director of National
Intelligence; or
(B) in the case of the Military Intelligence
Program, the Director, the Director of National
Intelligence, and the Secretary of Defense.
(b) Classified Information.--Any contents of any report required
under this Act, or the amendments made by this Act, that involve
information properly classified under criteria established by an
Executive order shall be presented to Congress separately from the rest
of such report.
(c) Use of Existing Resources.--To the extent practicable, the
Director and the head of each agency shall use existing procedures and
systems to carry out agency requirements under this Act, and the
amendments made by this Act.
SEC. 6. GAO AUDIT AND REPORTS.
Not later than 3 and 6 years after the date of the enactment of
this Act, the Comptroller General shall--
(1) conduct an audit relating to the programs and
operations of--
(A) the Office; and
(B) certain programs within the Office, including--
(i) the High Intensity Drug Trafficking
Areas Program;
(ii) the Drug-Free Communities Program; and
(iii) the campaign under section 1009(d) of
title 31, as added by section 2(c); and
(2) submit to the Director and the appropriate
congressional committees a report containing an evaluation of
and recommendations on the--
(A) policies and activities of the programs and
operations subject to the audit;
(B) economy, efficiency, and effectiveness in the
administration of the reviewed programs and operations;
and
(C) policy or management changes needed to prevent
and detect fraud and abuse in such programs and
operations.
SEC. 7. REPEALS.
(a) Repeals to the Law.--The following provisions are repealed:
(1) The Office of National Drug Control Policy
Reauthorization Act of 1998 (Public Law 105-277; 21 U.S.C. 1701
et seq.).
(2) Chapter 2 of the National Narcotics Leadership Act of
1988 (Public Law 100-690; 21 U.S.C. 1501 et seq.).
(3) Section 203 of the Office of National Drug Control
Policy Reauthorization Act of 2006 (Public Law 109-469; 21
U.S.C. 1708a).
(4) Section 1105 of the Office of National Drug Control
Policy Reauthorization Act of 2006 (Public Law 109-469; 21
U.S.C. 1701 note).
(5) Section 1110 of Office of National Drug Control Policy
Reauthorization Act of 2006 (Public Law 109-469; 21 U.S.C. 1705
note).
(6) Section 1110A of the Office of National Drug Control
Policy Reauthorization Act of 2006 (Public Law 109-469; 21
U.S.C. 1705 note).
(7) Section 4 of Public Law 107-82 (21 U.S.C. 1521 note).
(b) Effect on the Code.--The Law Revision Counsel shall ensure that
the website and any other publication issued after the date of the
enactment of this Act for the Office of the Law Revision Counsel shows
that the laws reflected in subchapter II of chapter 20 and chapter 22
of nonpositive law title 21 of the United States Code have been
repealed.
SEC. 8. DEFINITIONS.
In this Act, the terms ``agency'', ``appropriate congressional
committees'', ``Director'', ``drug'', ``emerging drug threat'',
``illicit drug use'', ``illicit drugs'', ``National Drug Control
Program Agencies'', and ``Office'' have the meaning given those terms
in section 1001 of title 31, United States Code, as added by section
2(c).
Passed the House of Representatives June 20, 2018.
Attest:
Clerk.
115th CONGRESS
2d Session
H. R. 5925
_______________________________________________________________________
AN ACT
To codify provisions relating to the Office of National Drug Control,
and for other purposes.